<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Autosomal dominant spinocerebellar ataxias</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Autosomal dominant spinocerebellar ataxias</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Autosomal dominant spinocerebellar ataxias</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Puneet Opal, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Huda Y Zoghbi, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Helen V Firth, DM, FRCP, FMedSci</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">April F Eichler, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 17, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The spinocerebellar ataxias (SCAs) are a genetically and clinically heterogeneous group of neurodegenerative disorders characterized by a slowly progressive cerebellar syndrome in association with oculomotor, retinal, pyramidal, extrapyramidal, sensory, and cognitive/behavioral symptoms that vary with the affected gene. Most SCAs are adult-onset, although childhood presentations occur in some forms.</p><p>A genetic diagnosis is possible for many but not all of the recognized SCAs, and most patients have one or more affected family members. Several forms share a common pathophysiology related to expansion of cytosine-adenine-guanine (CAG) repeats.</p><p>The autosomal dominant SCAs are reviewed here. Other causes of hereditary and nonhereditary ataxia are reviewed separately. (See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults"</a> and  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias"</a>.)</p><p class="headingAnchor" id="H4120397363"><span class="h1">OVERVIEW</span></p><p class="headingAnchor" id="H3320897037"><span class="h2">Nomenclature and classification</span><span class="headingEndMark"> — </span>The nomenclature of the autosomal dominant ataxias is complicated and has evolved over time.</p><p>SCAs were originally organized around phenotype (Harding classification) and later in order of the identification of their genetic loci (numeric SCA classification). Yet another proposal from the International Parkinson and Movement Disorder Society (MDS) spans a variety of movement disorders and attempts to classify genetic forms based on the most prominent movement disorder and the gene name, using the ATX prefix for ataxias [<a href="#rid1">1</a>].</p><p>Until the SCA and MDS classifications are harmonized, we will continue to use SCA nomenclature in this topic where relevant. Autosomal dominant hereditary ataxias recognized in the MDS classification that do not have an SCA designation are also included here. (See <a class="local">'Others'</a> below.)</p><p>There are yet other genetic disorders that are inherited in an autosomal dominant manner, which often present with prominent and progressive ataxia. These are discussed in this review to complete the differential diagnosis of these chronic, progressive ataxic syndromes. (See <a class="local">'Other autosomal dominant ataxias'</a> below.)</p><p>A number of other hereditary ataxias with other modes of inheritance or pathobiology are discussed separately. (See  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias"</a>.)</p><p class="headingAnchor" id="H3989561495"><span class="h2">Clinical spectrum</span><span class="headingEndMark"> — </span>Over 40 types of SCAs have been identified. Cerebellar ataxia is a feature of each type; other distinguishing features may suggest a particular type  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>).</p><p>However, only 60 to 75 percent of patients with SCA have variants in the known loci [<a href="#rid2">2</a>]. Furthermore, among patients with apparently idiopathic sporadic cerebellar ataxia (ie, no family history), an SCA variant (most often SCA6) or Friedreich ataxia can be identified in approximately 20 percent [<a href="#rid3">3</a>]. Online resources such as the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fomim%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2F1mEzbrra1EyPWuMKBWRSz2CpYoyP348HDYHpSCw69NK&amp;TOPIC_ID=6230" target="_blank">Online Mendelian Inheritance in Man</a> (OMIM) database can be used to keep up with advances in this area.</p><p class="headingAnchor" id="H3537603237"><span class="h3">CAG repeat disorders</span><span class="headingEndMark"> — </span>Several types of SCAs (SCA1, SCA2, SCA3, SCA6, SCA7, and SCA17) are associated with expansion of cytosine-adenine-guanine (CAG) repeats in the region that encodes for polyglutamine tracts in the protein products, similar to that seen in Huntington disease. (See  <a class="medical medical_review" href="/d/html/6182.html" rel="external">"Huntington disease: Genetics and pathogenesis"</a>.)</p><p>Wildtype chromosomes with a stable CAG repeat have 6 to 34 repeat units; more than 36 repeats results in an unstable, expanded, disease-causing allele [<a href="#rid4">4</a>]. Expansion of CAG repeats is thought to produce a toxic "gain of function" (ie, disease develops because the mutant form of the protein gains a new function, not because the protein loses its normal function).</p><p>The disorders associated with expansion of CAG repeats share several clinical features:</p><p class="bulletIndent1"><span class="glyph">●</span>They typically present in middle age, with progressive ataxia evolving over the ensuing 10 to 20 years.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The greater the number of CAG repeats on expanded alleles, the earlier the age of onset and more severe the disease. Thus, juvenile-onset disease typically is associated with very large expansions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As examples of the variability in onset, a prospective study reported the mean age of onset for several common types of SCAs as follows [<a href="#rid5">5</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>SCA1, 37 years (range 5 to 65)</p><p class="bulletIndent2"><span class="glyph">•</span>SCA2, 35 years (range 7 to 66)</p><p class="bulletIndent2"><span class="glyph">•</span>SCA3, 37 years (range 5 to 66)</p><p class="bulletIndent2"><span class="glyph">•</span>SCA6, 55 years (range 31 to 77)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The repeats show both somatic and germline instability. As a result, successive generations of affected families experience anticipation, a phenomenon characterized by earlier onset and a progressively worse phenotype in subsequent generations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Only a certain subset of neurons is vulnerable to dysfunction, even though the relevant protein is expressed widely throughout the brain and other tissues.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cerebellar atrophy is the most common reported finding. Brainstem atrophy is variable, being more characteristic of SCA1, SCA2, and SCA7. Neurodegeneration of the reticulotegmental nucleus of the pons has been reported for patients with SCA1, SCA2, and SCA3; this nucleus plays a role in the performance of horizontal smooth pursuit eye movements and in the accuracy of horizontal saccades [<a href="#rid6">6</a>].</p><p></p><p class="headingAnchor" id="H3120015541"><span class="h2">Diagnostic evaluation</span><span class="headingEndMark"> — </span>Issues specific to the evaluation of a patient with suspected SCA are discussed here. The etiologic evaluation of a patient with ataxia more generally is reviewed separately. (See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Etiologic evaluation'</a>.)</p><p class="headingAnchor" id="H3389897685"><span class="h3">Genetic testing</span><span class="headingEndMark"> — </span>In the setting of a patient who has a positive family history of cerebellar ataxia, genetic testing is the most efficient and definitive way to determine the cause of the symptoms and to identify the ataxia subtype. The few clinical differentiating features  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>) may suggest the likely candidate(s) for a stepwise screen. More commonly, however, an ataxia repeat expansion gene panel is an appropriate initial test. Most such panels including testing for SCA1, SCA2, SCA3, SCA6, SCA7, SCA8, SCA10, SCA17, and dentatorubral pallidoluysian atrophy (DRPLA).</p><p>Some patients are referred having previously undergone genome sequencing with uninformative results. Importantly, repeat expansions will <strong>not</strong> be reliably picked up by most clinical whole-exome or whole-genome sequencing tests unless enhanced bioinformatics or advanced sequencing technologies are used [<a href="#rid7">7</a>]. Online resources (eg, the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr%2F&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4tryNPgji1PaJ6Kbd%2Fo1hE9A6&amp;TOPIC_ID=6230" target="_blank">Genetic Testing Registry</a>) can be used to determine which SCA genes can be tested and the appropriate type of test.</p><p>Additional information on genetic testing for patients with progressive ataxia of unknown etiology is presented separately. (See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Genetic testing'</a>.)</p><p class="headingAnchor" id="H3268255470"><span class="h3">Neuroimaging features</span><span class="headingEndMark"> — </span>Cerebellar atrophy is the most common structural neuroimaging feature in patients with SCA. Among the SCAs, atrophy is most prominent in SCA2 and least prominent in the milder diseases, SCA5 and SCA6.</p><p>Brainstem atrophy, which would be expected to be almost universal, is characteristic of SCA1, SCA2, and SCA7. In one study, the degree of atrophy correlated with the neurologic deficit in SCA1 but not SCA2 [<a href="#rid8">8</a>]. Brainstem atrophy is minimal in SCA3 and DRPLA and is rare in SCA6.</p><p>Cerebral atrophy with compensatory enlargement of the lateral ventricles can be seen in SCA2, the infantile variant of SCA7, and DRPLA.</p><p>Magnetic resonance spectroscopy and positron emission tomography (PET) are sensitive for deterioration in patients with SCA when examined longitudinally and quantitatively; in this way they can demonstrate abnormalities not seen on magnetic resonance imaging (MRI). At present, these modalities are primarily being explored as potential biomarkers for clinical trials.</p><p class="headingAnchor" id="H4167726837"><span class="h3">Electrophysiologic testing</span><span class="headingEndMark"> — </span>Most SCAs cause defects in nerve conduction, especially SCA4. The predominant axonal neuropathy primarily affects sensory neurons, and sural nerve action potentials often are absent. However, these studies are rarely useful in determining the type of ataxia.</p><p>On the other hand, visual-evoked potentials may suggest SCA7 because of the characteristic macular degeneration, whereas interictal electroencephalographic (EEG) abnormalities may suggest DRPLA. Seizures also are common in SCA10, but the interictal EEG is typically normal.</p><p class="headingAnchor" id="H605308128"><span class="h2">Prognosis</span><span class="headingEndMark"> — </span>The age of onset and rate of disability progression for the more common SCAs vary according to individual differences in the length of the causative CAG trinucleotide repeat. Most of the available data concern the four most common types of SCAs, which are SCA1, SCA2, SCA3, and SCA6.</p><p>Generally, patients require a wheelchair by 10 to 15 years after symptom onset. Several studies have found that SCA1 is associated with more rapid disease progression and shorter survival compared with SCA2, SCA3, and SCA6 [<a href="#rid5">5,9-11</a>]. In one of these reports, the median age at death for patients with SCA1 was 56 years [<a href="#rid9">9</a>]. Higher baseline scores on the Scale for the Assessment and Rating of Ataxia (SARA) were associated with shorter survival for all four subtypes [<a href="#rid10">10</a>].</p><p>Disability and mortality data for the other types of SCAs are limited. However, in most there is disability progression over one to two decades on average, and lifespan is shortened, though some types are compatible with a normal lifespan [<a href="#rid12">12</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Treatment</span><span class="headingEndMark"> — </span>No effective treatment is available for the SCAs. Investigational approaches include interventions to suppress polyglutamine neurotoxicity and genetic therapies to reduce polyglutamine gene products [<a href="#rid13">13</a>]. Treatments with some promise include antisense oligonucleotides, ribonucleic acid (RNA) interference, and stem cell therapies.</p><p class="headingAnchor" id="H4"><span class="h1">SPECIFIC DISORDERS</span></p><p class="headingAnchor" id="H5"><span class="h2">SCA1</span><span class="headingEndMark"> — </span>In different populations, SCA1 accounts for 3 to 16 percent of autosomal dominant cerebellar ataxias [<a href="#rid14">14-18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SCA1 typically presents in the third to fourth decade of life, but tremendous variability in onset and clinical severity exists. It is characterized clinically by progressive cerebellar ataxia, dysarthria, and bulbar dysfunction. Other findings include hyperreflexia, increased tone, extensor plantar responses, and, in some patients, masking of these upper motor neuron findings by peripheral nervous system disease that results in wasting of the extremities and generalized fasciculations.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Pathologically, SCA1 is characterized by degeneration of cerebellar Purkinje cells, brainstem cranial nerve and inferior olivary nuclei, and the spinocerebellar tracts [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SCA1 is caused by a cytosine-adenine-guanine (CAG) repeat expansion on chromosome 6p22.3 in the coding region of the ataxin 1 (<em>ATXN1</em>) gene [<a href="#rid20">20</a>]. Expanded <em>ATXN1</em> genes contain from 36 to 81 uninterrupted CAG repeats (normal alleles have 6 to 44 repeats; alleles with 36 to 44 CAG repeats are considered normal if they are interrupted by a few cytosine-adenine-thymine [CAT] units). Mutant <em>ATXN1</em> aggregates into single nuclear inclusions [<a href="#rid21">21</a>]. This aggregation reflects, at least in part, resistance of the mutant protein to degradation. The pathogenetic role of the nuclear inclusions themselves is uncertain [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1">The pathogenesis of SCA1 involves primarily a gain-of-function mechanism and, to a lesser degree, a partial loss-of-function mechanism for <em>ATXN1</em> [<a href="#rid23">23</a>]. In addition to the expanded polyglutamine tract, which is located towards the N-terminus of <em>ATXN1</em>, other important mediators include the ATXN1 and HMG-box protein 1 (AXH) domain (amino acids 570 to 689), the nuclear localization sequence (NLS; amino acids 771 to 776), and the C-terminal amino acid of the NLS, serine 776 (Ser776). The AXH domain forms an oligonucleotide-binding fold [<a href="#rid24">24</a>] and also interacts with a number of transcription factors and proteins [<a href="#rid24">24,25</a>], including the capicua transcriptional repressor (CIC) protein [<a href="#rid26">26</a>]. The NLS directs mutant <em>ATXN1</em> to the nucleus, which is necessary for disease to occur [<a href="#rid22">22</a>]. Phosphorylation of Ser776 is also necessary for toxicity of mutant <em>ATXN1</em> [<a href="#rid27">27</a>] and is important for the interaction of <em>ATXN1</em> with a protein called RNA-binding motif protein 17 (RBM17) [<a href="#rid28">28,29</a>].</p><p></p><p class="bulletIndent1">One model of <em>ATXN1</em> toxicity postulates that wildtype <em>ATXN1</em> exists in an equilibrium of two main protein complexes, one involving <em>ATXN1</em> (not phosphorylated at Ser776) associated with CIC, and the other involving <em>ATXN1</em> (phosphorylated at Ser776) associated with 14-3-3, RBM17, and possibly other proteins [<a href="#rid30">30,31</a>]. The expanded polyglutamine tract of mutant <em>ATXN1</em> enhances the function of these complexes (gain of function) to drive toxicity.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Investigational therapies</strong> – Interventions that lower ATXN1 levels could be useful for identifying therapeutic targets in SCA1. One approach is illustrated by a study that screened for kinase genes involved in the regulation of ATXN1 protein levels [<a href="#rid32">32</a>]. The investigators found that multiple components of the RAS-MAPK-MSK1 signaling cascade play a role in modulating ATXN1 protein levels in <em>Drosophila</em> and human cell lines. In addition, pharmacologic inhibitors of the pathway reduced ATXN1 levels. Further studies are needed to identify additional pathways that may be involved in ATXN1 regulation and to determine whether manipulating these pathways is beneficial in SCA1.</p><p></p><p class="bulletIndent1">The same type of approach may be useful to look for therapeutic targets in other neurodegenerative diseases characterized by the toxic accumulation of mutant proteins. Other approaches that may prove to be of clinical relevance include the proof-of-concept preclinical data using either antisense oligonucleotides to lower ATXN1 or a microRNA that targets ATXN1 RNA [<a href="#rid33">33,34</a>].</p><p></p><p class="headingAnchor" id="H6"><span class="h2">SCA2</span><span class="headingEndMark"> — </span>In different populations, SCA2 accounts for 6 to 18 percent of SCA kindreds [<a href="#rid14">14-17,35</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SCA2 is distinguished from SCA1 by the presence of slow saccadic eye movements [<a href="#rid36">36</a>]. Clinical features are otherwise similar to those of SCA1. (See <a class="local">'SCA1'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SCA2 results from expanded polyglutamine tracts in the ataxin 2 (<em>ATXN2</em>) gene on chromosome 12q24, which encodes a protein called ataxin 2 [<a href="#rid37">37,38</a>]. Ataxin 2 contains structural elements that appear to be important in RNA splicing. In contrast to the nuclear inclusions in SCA1, mutant ataxin 2 is associated with cytoplasmic microaggregates [<a href="#rid39">39</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype-phenotype correlations</strong> – Disease-causing alleles usually contain 35 to 64 CAG repeats (normal 14 to 31 repeats). An inverse relationship exists between disease onset and severity and the number of CAG repeats [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When <em>ATXN2</em> alleles contain more than 200 repeats, the disease can present as early as infancy with hypotonia, developmental delay, infantile spasms, autonomic dysfunction, dysphagia, and retinitis pigmentosa [<a href="#rid42">42,43</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>On the other hand, disease onset in late adulthood, manifested as ataxia, slow saccades, and hyporeflexia, has been described in two patients with 33 CAG repeats [<a href="#rid44">44</a>].</p><p></p><p class="bulletIndent1">In one ethnic Chinese family, SCA2 has been associated with a predominant phenotype resembling dopa-responsive Parkinson disease or an ataxia-parkinsonism phenotype similar to progressive supranuclear palsy [<a href="#rid45">45</a>]. (See  <a class="medical medical_review" href="/d/html/4904.html" rel="external">"Diagnosis and differential diagnosis of Parkinson disease"</a>.)</p><p></p><p class="bulletIndent1">In addition, occasional patients with polyglutamine expansions in <em>ATXN2</em> have a phenotype of motor neuron disease similar to or indistinguishable from amyotrophic lateral sclerosis. (See  <a class="medical medical_review" href="/d/html/5156.html" rel="external">"Epidemiology and pathogenesis of amyotrophic lateral sclerosis", section on 'Genetic susceptibility in sporadic ALS'</a>.)</p><p></p><p class="bulletIndent1">Genetic background also influences the phenotype in geographically distinct families. For example, cognitive decline has been described in an Italian family [<a href="#rid46">46,47</a>], and chorea and dystonia have been described in families from Tunis and Martinique [<a href="#rid48">48,49</a>].</p><p></p><p class="headingAnchor" id="H7"><span class="h2">SCA3 (Machado-Joseph disease)</span><span class="headingEndMark"> — </span>SCA3, also known as Machado-Joseph disease (MJD), is the most common of the autosomal dominant SCAs. It is present in 21 to 23 percent of kindreds in the United States [<a href="#rid15">15,16,18</a>], 12 percent in Australia [<a href="#rid17">17</a>], and as many as 48 percent in China [<a href="#rid14">14</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – MJD can be associated with a variety of symptoms other than ataxia. They include:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Slow saccades and saccadic pursuit</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Lid retraction that gives the impression of a persistent stare</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of brainstem dysfunction, such as dysarthria, difficulty in swallowing, poor cough, and tongue fasciculations</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Signs of upper and lower motor neuron dysfunction; thus, tone can range from hypotonia to rigidity, reflexes can range from absent to exaggerated, and the plantar response is usually extensor</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Extrapyramidal features including rigidity and dystonia</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Muscle cramps and fasciculations [<a href="#rid50">50</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Cognitive impairment, including verbal and visual memory deficits, impairment of verbal fluency, and visuospatial and constructional dysfunction [<a href="#rid51">51</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autonomic dysfunction with symptoms such as cold intolerance, nocturia, and orthostatic dizziness [<a href="#rid52">52</a>]</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Sleep disorders, including rapid eye movement sleep behavior disorder, restless legs syndrome, insomnia, and excessive daytime sleepiness [<a href="#rid53">53,54</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – MJD is caused by CAG expansions in the ataxin 3 (<em>ATXN3</em>) gene (previously known as the <em>SCA3</em> or <em>MJD</em> gene) on the long arm of chromosome 14 (14q32) [<a href="#rid55">55,56</a>]; it encodes a protein called ataxin 3 [<a href="#rid55">55</a>]. The mutant gene has an increased number of CAG repeats (40 to more than 200 versus 12 to 41 [interrupted] in the wildtype allele).</p><p></p><p class="bulletIndent1">Wildtype ataxin 3 is predominantly cytoplasmic, whereas mutant ataxin 3 is localized within the nucleus of neuronal cells [<a href="#rid57">57</a>]. The mutant protein forms nuclear inclusions and is associated with cell degeneration [<a href="#rid58">58,59</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Genotype-phenotype correlations</strong> – Phenotypic variation is most likely a reflection of the number of CAG repeats and other genetic factors [<a href="#rid60">60</a>].</p><p></p><p class="headingAnchor" id="H8"><span class="h2">SCA4</span><span class="headingEndMark"> — </span>SCA4 has few features that distinguish it from the other hereditary ataxias, except perhaps for an exaggerated sensory axonal neuropathy and extensor plantar reflexes [<a href="#rid61">61</a>]. The gene locus maps to chromosome 16q22 [<a href="#rid61">61,62</a>].</p><p class="headingAnchor" id="H9"><span class="h2">SCA5</span><span class="headingEndMark"> — </span>SCA5 is characterized by an almost pure cerebellar syndrome. It is a relatively mild disorder that typically begins between the ages of 20 and 30 and progresses slowly [<a href="#rid63">63</a>], though infantile onset with a more severe phenotype has also been reported [<a href="#rid64">64</a>]. MRI reveals global cerebellar atrophy [<a href="#rid63">63</a>].</p><p>The gene locus is in the centromeric region of chromosome 11 [<a href="#rid65">65</a>], and the disease has been associated with variants in the spectrin beta, nonerythrocytic 2 (<em>SPTBN2</em>) gene [<a href="#rid66">66</a>]. The original kindred was descended from the paternal grandparents of Abraham Lincoln.</p><p class="headingAnchor" id="H10"><span class="h2">SCA6</span><span class="headingEndMark"> — </span>SCA6 accounted for 15 to 17 percent of dominant cerebellar ataxias in two series [<a href="#rid16">16,17</a>]. A population-based molecular genetics study found that the point prevalence of SCA6 in the northeast region of England was 1.59 in 100,000, and the number of individuals who had or were at risk of developing SCA was at least 1 in 19,000 [<a href="#rid67">67</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SCA6 shares many clinical features with SCA5 [<a href="#rid68">68-70</a>]. It is associated with slowly progressive cerebellar ataxia that begins between the ages of 20 and 60; global cerebellar atrophy is seen on MRI [<a href="#rid69">69,70</a>]. Other clinical features that may be seen include horizontal and vertical nystagmus and an abnormal vestibulo-ocular reflex [<a href="#rid68">68</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SCA6 is a polyglutamine disorder caused by an expanded CAG repeat in the calcium voltage-gated channel subunit alpha1 A (<em>CACNA1A</em>) gene, but the CAG expansion is relatively small (21 to 33 repeats versus fewer than 18 in unaffected subjects).</p><p></p><p class="bulletIndent1">In one series of Japanese patients with SCA6, 9 of 35 had no apparent family history of ataxia; these patients had smaller CAG repeats (21 or 22) and later age of onset (65 years) [<a href="#rid70">70</a>]. A similar finding was noted in another report of patients with apparently idiopathic sporadic cerebellar ataxia. A variant could be identified in 19 percent; SCA6 was the disorder most commonly identified in patients with late-onset disease (47 to 68 years of age) [<a href="#rid3">3</a>]. One patient who was homozygous for the SCA6 variant had an earlier age of onset and more severe disease than did her heterozygous sister [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">The product of the <em>CACNA1A</em> gene on 19p13 is the alpha-1A subunit of the P/Q type calcium channel [<a href="#rid71">71</a>]. Possible mechanisms of neuronal cell degeneration include increased calcium entry and cytoplasmic aggregates of channel protein [<a href="#rid72">72,73</a>].</p><p></p><p class="bulletIndent1">The <em>CACNA1A</em> gene has been implicated in two other disorders: episodic ataxia type 2 and familial hemiplegic migraine [<a href="#rid74">74,75</a>]. Although the pathogenic variants are different, some overlap of symptoms exists among these disorders. SCA6 can present with intermittent ataxia in the early stages, similar to episodic ataxia, and all three conditions often are associated with cerebellar atrophy. (See  <a class="medical medical_review" href="/d/html/6234.html" rel="external">"Overview of the hereditary ataxias", section on 'Episodic ataxia type 2'</a> and  <a class="medical medical_review" href="/d/html/14112.html" rel="external">"Hemiplegic migraine", section on 'Familial hemiplegic migraine'</a>.)</p><p></p><p class="headingAnchor" id="H11"><span class="h2">SCA7</span><span class="headingEndMark"> — </span>SCA7 accounts for approximately 2 to 5 percent of dominant SCAs [<a href="#rid16">16,17</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SCA7 has a variable clinical expression, depending in part upon the age at onset [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>When the onset is in childhood, seizures, myoclonus, and cardiac involvement accompany the ataxia, and visual loss develops early in the disease course. Extremely long (&gt;150) CAG repeats are associated with onset in infancy and evidence of systemic disease [<a href="#rid77">77</a>]. A severe infantile phenotype associated with over 200 CAG repeats has also been described [<a href="#rid76">76</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In adult-onset cases, smaller repeat expansions tend to manifest first as ataxia, whereas larger repeats can cause pigmentary macular degeneration, leading to visual loss before ataxia develops [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1">This visual loss had been thought to be unique to SCA7 [<a href="#rid79">79</a>], but retinal degeneration has been documented in childhood-onset cases of SCA2 and SCA1 caused by very large repeats. Nevertheless, in adults, defects in color vision and electroretinogram abnormalities might suggest the diagnosis early in the disease course [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SCA7 is a glutamine repeat disorder that maps to chromosome 3p12 [<a href="#rid78">78,79</a>]. The number of CAG repeats varies between 37 and 306 (normal 4 to 35). Marked intergenerational instability is present, with expansion particularly likely upon paternal transmission [<a href="#rid79">79,80</a>].</p><p></p><p class="bulletIndent1">The product of the SCA7 gene is called ataxin 7 and is preferentially expressed in neurons [<a href="#rid81">81</a>]. Mice overexpressing mutant ataxin 7, but not wildtype ataxin 7, have features similar to those of the human disease, with neurodegeneration involving the cerebellum and retina [<a href="#rid82">82</a>].</p><p></p><p class="headingAnchor" id="H12"><span class="h2">SCA8</span><span class="headingEndMark"> — </span>SCA8 accounts for approximately 3 to 5 percent of SCAs worldwide [<a href="#rid83">83</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – SCA8 is difficult to distinguish clinically from the other SCAs. Affected patients typically have a slowly progressive, predominantly cerebellar ataxia affecting gait, swallowing, speech, and limb and eye movements, with variable age at onset [<a href="#rid84">84,85</a>]. Marked cerebellar atrophy is found on MRI or computed tomography (CT) scan [<a href="#rid85">85</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathology</strong> – Neurodegeneration of Purkinje, inferior olivary, and nigral cells, accompanied by periaqueductal gliosis, was described in one Japanese family [<a href="#rid86">86</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – SCA8 is unusual because the pathogenesis involves a cytosine-thymine-guanine (CTG) expansion in the noncoding region of the ATXN8 opposite strand IncRNA (<em>ATXN8OS</em>) gene on chromosome 13q21 (70 to 250 repeats compared with 15 to 50 in unaffected subjects [<a href="#rid87">87</a>]) and a complementary CAG repeat in the ataxin 8 (<em>ATXN8</em>) gene [<a href="#rid88">88,89</a>]. Oddly, it is this particular range of repeats that is pathogenic, as opposed to any expansion; some unaffected individuals bear hundreds of repeats.</p><p></p><p class="bulletIndent1">The CTG expansion is transcribed in both the forward and reverse directions to yield RNA with a noncoding cytosine-uracil-guanine (CUG) expansion from the<em> ATXN8OS</em> gene and a CAG transcript from the<em> ATXN8</em> gene that encodes a string of polyglutamines [<a href="#rid90">90</a>]. It is likely that both these products act in dominant toxic pathways. Genetic analysis of 37 families with SCA8 ataxia found that SCA8 expansions arose independently on three different haplotypes, supporting the direct role of CTG expansion in disease pathogenesis [<a href="#rid91">91</a>].</p><p></p><p class="bulletIndent1">The CTG expansion found in SCA8 shows dramatic genetic instability and age-dependent reduced disease penetrance. As an example, only one or two individuals in a given family may be affected by the disease, despite dominant inheritance. A maternal penetrance bias may exist, as CTG repeats tend to expand in mothers and contract in fathers (ie, fewer repeats in sperm than blood) [<a href="#rid84">84,89</a>]. The reduced penetrance in fathers may make the disease appear recessive or sporadic [<a href="#rid84">84</a>].</p><p></p><p class="headingAnchor" id="H13"><span class="h2">SCA types 9 to 20</span><span class="headingEndMark"> — </span>The remaining types of SCA are rare and less well characterized. Types 21 and higher are described in the sections that follow. (See <a class="local">'SCA types 21 to 48'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA9</strong> has not been assigned to a clinical disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA10</strong> exhibits phenotypic variability and is characterized by seizures and pure cerebellar ataxia in Mexican families [<a href="#rid92">92</a>], cerebellar ataxia without epilepsy in Brazilian families [<a href="#rid93">93</a>], and extrapyramidal signs, seizures, and ataxia in an Argentinean family [<a href="#rid94">94</a>].</p><p></p><p class="bulletIndent1">SCA10 exhibits anticipation, and the locus maps to chromosome 22q13 [<a href="#rid95">95,96</a>]. The disease is caused by expansion of adenine-thymine-thymine-cytosine-thymine (ATTCT) pentanucleotide repeats in the ataxin 10 (<em>ATXN10</em>) gene initially identified in five Mexican families; normal alleles bear 10 to 22 repeats, while disease-causing alleles contain 800 to 4500 repeats [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA11</strong> is a relatively mild, pure cerebellar ataxia caused by variants in the tau tubulin kinase 2 (<em>TTBK2</em>) gene with a locus at 15q14-q21.3 [<a href="#rid98">98,99</a>]. The <em>TTBK2</em> gene encodes tau tubulin kinase 2, and neuropathologic examination of one affected individual revealed tau deposition and cerebellar degeneration [<a href="#rid99">99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA12</strong> is a trinucleotide repeat disorder caused by a CAG trinucleotide expansion in the protein phosphatase 2 regulatory subunit Bbeta (<em>PPP2R2B</em>) gene encoding a brain-specific regulatory subunit of protein phosphatase 2A [<a href="#rid100">100</a>]. The normal range of repeats is 7 to 28; disease alleles bear 43 to 78 repeats [<a href="#rid101">101</a>]. This ataxia often is complicated by tremor and dementia in the later stages. The genetic locus is 5q31-q33.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA13</strong> is characterized by cerebellar ataxia and intellectual disability [<a href="#rid102">102</a>]. The gene locus is on chromosome 19q13, and heterozygous variants of the potassium voltage-gated channel subfamily C member 3 (<em>KCNC3</em>) gene are associated with the disorder [<a href="#rid103">103</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA14</strong> is not a trinucleotide repeat disorder but rather is caused by variants in the protein kinase C gamma (<em>PRKCG</em>) gene, located on chromosome 19q13 [<a href="#rid104">104-108</a>]. SCA14 is characterized by slow progression and long duration. The disorder can have either a late onset (≥39 years) as pure cerebellar ataxia or an earlier onset with intermittent myoclonus followed by ataxia.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA15</strong> is a very slowly progressive, pure cerebellar ataxia, with onset occurring from mid-childhood to middle age [<a href="#rid109">109-112</a>]. Additional clinical features may include a mild postural or action tremor and titubation. Neuroimaging typically reveals atrophy of the cerebellum, especially the vermis, but the cerebral hemispheres and brainstem are unaffected. Although initial analysis seemingly excluded the inositol 1,4,5-trisphosphate receptor type 1 (<em>ITPR1</em>) gene [<a href="#rid111">111</a>], later studies confirmed that SCA15 is caused by deletions or missense variants in the <em>ITPR1</em> gene [<a href="#rid113">113,114</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA16</strong> is now thought to be the same disorder as SCA15 [<a href="#rid115">115,116</a>]. It was originally identified as an autosomal dominant cerebellar ataxia in four generations of a Japanese family [<a href="#rid110">110,117</a>]. While initial linkage analysis suggested the locus was on chromosome 8q22.1-24.1 [<a href="#rid110">110</a>], a later analysis suggested that SCA16 links with 3p26.2pter, a region that partly overlaps the SCA15 region [<a href="#rid117">117</a>]. A heterozygous deletion in the <em>ITPR1</em> gene, the causative gene for SCA15, was then demonstrated in a family with SCA16, confirming that SCA16 is the same disorder as SCA15 [<a href="#rid115">115</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA17</strong> is an autosomal dominant cerebellar ataxia first described in four Japanese pedigrees [<a href="#rid118">118</a>]. It is caused by an abnormal CAG or CAA expansion in the TATA-box binding protein (<em>TBP</em>) gene, a general transcription initiation factor. The age of onset ranges from 19 to 48 years and is inversely related to the number of CAG repeats in the <em>TBP</em> gene (≤40 normally, 41 to 45 reduced penetrance, 46 to 66 full penetrance/disease causing) [<a href="#rid119">119</a>]. Most individuals present between the ages of 20 and 30 with gait ataxia and dementia, progressing over several decades to include bradykinesia, dysmetria, dysdiadochokinesis, hyperreflexia, and paucity of movement. One family with SCA17 has been described with a Huntington disease-like syndrome, including generalized chorea [<a href="#rid120">120</a>]. Diffuse cortical and cerebellar atrophy is present on neuroimaging in all patients.</p><p></p><p class="bulletIndent1">Mouse models of SCA17 have been generated by expressing TBP with expanded polyglutamine tracts under the mouse prion promoter. These mice demonstrate a neurodegenerative syndrome. Moreover, biochemical experiments suggest that the expanded polyglutamine tracts reduce TBP dimerization but enhance the interaction of TBP with the general transcription factor IIB, implicating the polyglutamine domain of TBP in transcriptional regulation [<a href="#rid121">121</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA18</strong> is an autosomal dominant disorder described in an American family of Irish ancestry with ataxia, pyramidal tract signs, muscle weakness, sensory axonal neuropathy, and mild cerebellar atrophy [<a href="#rid122">122</a>]. Haplotype analysis links the disorder to a region at 7q22-q32.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Both <strong>SCA19</strong>, originally identified in a Dutch family [<a href="#rid123">123,124</a>], and <strong>SCA22</strong>, originally identified in a Taiwanese family [<a href="#rid125">125</a>], are autosomal dominant allelic conditions caused by variants in the potassium voltage-gated channel subfamily D member 3 (<em>KCND3</em>) gene that encodes for Kv4.3, a voltage-gated potassium channel [<a href="#rid126">126-128</a>]. SCA19/22 have been identified in multiple unrelated families of varied ethnicities. The phenotype is predominantly a cerebellar syndrome, but more severe cases can be associated with cognitive impairment or myoclonus.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA20</strong> is described in a family of Anglo-Celtic ancestry with a slowly progressive, autosomal dominant SCA [<a href="#rid129">129</a>]. Age of onset in 14 family members was 19 to 64 years (mean 46.5). Dysarthria is the most common initial symptom. Gait or upper limb ataxia follows in most. Palatal tremor and dysphonia are distinguishing clinical features. Dentate nucleus calcification can be visualized by brain imaging with CT or MRI. The disease locus maps to chromosome 11, where a duplication containing at least 12 genes has been identified [<a href="#rid130">130</a>].</p><p></p><p class="headingAnchor" id="H14"><span class="h2">SCA types 21 to 48</span><span class="headingEndMark"> — </span>Additional rare types of SCA include those numbered from 21 through 37  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>).</p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA21</strong> was first identified in four generations of a French family [<a href="#rid131">131</a>]. Characteristics include early onset, mild to severe cognitive impairment, motor clumsiness, and slow progression [<a href="#rid132">132,133</a>]. The disorder is caused by variants in the transmembrane protein 240 (<em>TMEM240</em>) gene located on chromosome 1p36.33.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>As noted above, <strong>SCA22</strong> and <strong>SCA19</strong> are allelic conditions identified in multiple unrelated families of varied ethnicities. The phenotype is predominantly a cerebellar syndrome, but more severe cases can be associated with cognitive impairment or myoclonus. SCA19/22 are caused by variants in the <em>KCND3</em> gene that encodes for Kv4.3, a voltage-gated potassium channel [<a href="#rid126">126-128</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA23</strong> is described in a Dutch family and is characterized by a late-onset (age &gt;40 years), slowly progressive SCA with variable dysarthria, ocular dysmetria, and distal sensory deficits [<a href="#rid134">134</a>]. Variants in the prodynorphin (<em>PDYN</em>) gene located on chromosome region 20p13 are causative [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA24</strong> is a recessively inherited ataxia and has been redesignated as autosomal recessive spinocerebellar ataxia type 4 (SCAR4). This condition is described in a Slovenian family with progressive ataxia and disruption of visual fixation by large horizontal saccadic intrusions [<a href="#rid136">136,137</a>]. Corticospinal signs and an axonal sensorimotor neuropathy are additional manifestations. The disorder is due to a variant in the vacuolar protein sorting 13 homolog D (<em>VPS13D</em>) gene on chromosome region 1p36.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA25</strong> is described in a large French family and is characterized by cerebellar ataxia and sensory neuropathy [<a href="#rid138">138</a>]. The responsible locus maps to chromosome 2. The phenotype is highly variable regarding age of onset, severity, and clinical manifestations, ranging from infantile-onset cerebellar ataxia with pure sensory neuropathy suggestive of Friedreich ataxia to a form with mild cerebellar ataxia and prominent sensory neuropathy suggestive of Charcot-Marie-Tooth disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA26</strong> is described in a Norwegian family and is characterized by a pure, slowly progressive cerebellar ataxia with autosomal dominant inheritance [<a href="#rid139">139</a>]. The responsible variant is a coding variant in the eukaryotic translation elongation factor 2 (<em>EEF2</em>) gene that maps to chromosome 19p13.3 [<a href="#rid140">140</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA27A</strong> is described in a large Dutch family and is characterized by early-onset tremor, dyskinesia, slowly progressive cerebellar ataxia, cognitive impairment, and a variant in the fibroblast growth factor 14 (<em>FGF14</em>) gene on chromosome 13q34. [<a href="#rid141">141,142</a>]. A variant in <em>FGF14</em> has also been reported in a German patient with familial ataxia [<a href="#rid143">143</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA27B</strong> due to heterozygous pathogenic guanine-adenine-adenine (GAA) repeat expansion deep in the first intron of <em>FGF14</em> was first identified in 2023 as a cause of familial and sporadic late-onset ataxia in independent cohorts of patients and families from Quebec, Germany, Australia, and South India [<a href="#rid144">144,145</a>]. Additional studies are needed to better define prevalence and phenotypic spectrum, but this appears to be an important cause of late-onset cerebellar ataxia (identified in 13 percent of one French cohort with otherwise unexplained adult-onset cerebellar ataxia) [<a href="#rid146">146</a>]. Rare individuals with biallelic<em> FGF14</em> GAA repeat expansions have also been identified with the onset of ataxia before the age of 30 years [<a href="#rid147">147</a>].</p><p></p><p class="bulletIndent1">Initial genotype-phenotype analysis suggests incomplete penetrance of expansions with 250 to 300 repeats and full penetrance of expansions with &gt;300 repeats [<a href="#rid144">144</a>]. The intronic (noncoding) GAA repeat appears to be highly unstable and associated with reduced male transmission due to contraction of repeat expansion during paternal meiosis; this phenomenon can lead to "generation skipping" when a subpathogenic allele is inherited and re-expands in a subsequent parent-offspring transmission.</p><p></p><p class="bulletIndent1">The phenotypic spectrum is evolving. Among 122 patients with confirmed GAA<em>-FGF14</em>-related ataxia (≥250 GAA repeats), the median age of onset was 55 years, and approximately half of patients had episodic ataxia and/or downbeat nystagmus as early symptoms [<a href="#rid144">144</a>]. In a smaller cohort of sporadic cases, the median age at onset was 67.5 years, and 73 percent were male [<a href="#rid146">146</a>]. The main clinical features that helped to distinguish SCA27B cases from idiopathic late-onset ataxia were older age, vertigo, diplopia, oculomotor disorders (eg, nystagmus), absence of dysautonomia and orthostatic hypotension, and presence of mild sensorimotor axonal neuropathy. Some patients have a phenotype that resembles cerebellar ataxia, neuropathy, and vestibular areflexia syndrome (CANVAS) [<a href="#rid148">148</a>]. (See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Autosomal recessive ataxias'</a>.)</p><p></p><p class="bulletIndent1">Disease progression appears to be slow and cognitive function relatively preserved in most patients [<a href="#rid149">149</a>]. Symptomatic benefit from 4-aminopyridine has been described and warrants further study [<a href="#rid149">149</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA28</strong> is described in an Italian family and is characterized by a juvenile-onset (mean age 19.5 years), slowly progressive cerebellar ataxia with eye movement abnormalities and, in some cases, pyramidal tract signs [<a href="#rid150">150</a>]. Inheritance is autosomal dominant. The disorder is caused by heterozygous missense variants in the mitochondrial protease gene AFG3-like matrix AAA peptidase subunit 2 (<em>AFG3L2</em>) on chromosome 18p [<a href="#rid151">151</a>]. Intriguingly, the protein encoded by this gene is a homolog of paraplegin, a protein mutated in one form of hereditary spastic paraplegia (SPG7).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA29</strong> maps to chromosome 3p26 and may be an allelic variant of SCA15 [<a href="#rid152">152</a>]. It is characterized by early-onset, nonprogressive ataxia with variable atrophy of the cerebellar vermis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA30</strong> is an autosomal dominant form described in an Australian family of Anglo-Celtic ancestry [<a href="#rid153">153</a>]. Clinical features include onset in mid- to late life of a slowly progressive, relatively pure ataxia with hypermetric saccades and minor pyramidal signs. Brain MRI shows atrophy of the cerebellar vermis and cerebellar hemisphere. The disorder maps to chromosome 4q34.3-q35.1. While the responsible gene is not established, the teneurin transmembrane protein 3 (<em>TENM3</em>) gene is a candidate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA31</strong>, previously called 16q22-linked autosomal dominant spinocerebellar ataxia, is characterized in Japanese populations by late-onset cerebellar ataxia and reduced muscle tone with or without sensorineural hearing loss [<a href="#rid153">153-155</a>]. Its locus is on chromosome 16q22.1, close to SCA4. It is caused by an insertion containing pentanucleotide repeats, including a long (thymine-guanine-guanine-adenine-adenine [TGGAA])n sequence, within an intronic region shared by the thymidine kinase 2 (<em>TK2</em>) gene and the brain expressed associated with NEDD4 (BEAN) family of genes [<a href="#rid156">156</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA32</strong> is described in a single Chinese family with autosomal dominant ataxia [<a href="#rid157">157</a>]. Cognitive impairment affects those with onset before age 40. All males are infertile due to azoospermia. The disorder links to a locus on chromosome 7q32-q33.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA33</strong> has not been assigned to a clinical disorder.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA34</strong> is reported in a French Canadian kindred with autosomal dominant SCA and skin lesions [<a href="#rid158">158</a>], caused by a heterozygous missense variant in the ELOVL fatty acid elongase 4 (<em>ELOVL4</em>) gene [<a href="#rid159">159</a>]. SCA34 has also been identified in two Japanese families with slowly progressive cerebellar ataxia and pyramidal signs but no skin lesions [<a href="#rid160">160</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA35</strong> is described in several families of Han Chinese descent [<a href="#rid161">161-163</a>]. Onset is at a mean age of 44 years, and the disorder is notable for slowly progressive gait and limb ataxia and mild dysarthria. SCA35 is caused by heterozygous variants in the transglutaminase 6 (<em>TGM6</em>) gene located on chromosome 20p13.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA36</strong> was first reported in a number of families from Japan [<a href="#rid164">164-166</a>] and Spain [<a href="#rid167">167</a>] but has since been found in various ethnic backgrounds [<a href="#rid168">168</a>]. The clinical features include late onset (mean age of 53 years in Japan) with cerebellar dysfunction manifesting as truncal ataxia, dysarthria, and limb ataxia. Motor neuron involvement occurred in most patients from Japan with longer disease duration [<a href="#rid164">164,165</a>], while sensorineural hearing loss occurred as an early feature in most cases from Spain [<a href="#rid167">167</a>]. SCA36 is caused by expansion of an intronic guanine-guanine-cytosine-cytosine-thymine-guanine (GGCCTG) hexanucleotide repeat in the NOP56 ribonucleoprotein (<em>NOP56</em>) gene located on chromosome 20p13.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA37</strong> is a late-onset (mean age 48 years, range 38 to 64 years) cerebellar ataxia identified in a Spanish kindred that links to chromosome 1p32 [<a href="#rid169">169,170</a>]. Prominent clinical features include falls, dysarthria, clumsiness, and abnormal vertical eye movements.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA38</strong>, identified in several European families, is characterized by a late-onset (34 to 51 years), pure cerebellar phenotype with truncal ataxia, gait disturbance, and slow progression; associated features include gaze-evoked nystagmus, dysarthria, and limb ataxia. It is caused by variants in the ELOVL fatty acid elongase 5 (<em>ELOVL5</em>) gene [<a href="#rid171">171</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA40</strong>, identified in a family from China, is notable for late onset (fifth decade) of truncal and gait ataxia; additional features include dysarthria, ocular dysmetria, and pyramidal involvement with hyperreflexia and spasticity [<a href="#rid172">172</a>]. A missense variant in the coiled-coil domain-containing 88C (<em>CCDC88C</em>) gene is the cause.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA41</strong> was described in one 40-year-old male who presented with progressive imbalance and gait ataxia. A missense variant in the transient receptor potential cation channel subfamily C member 3 (<em>TRPC3</em>) gene is implicated as the cause [<a href="#rid173">173</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA42</strong>, identified in multiple French and Japanese families, has a varied age of onset. The main features are ataxia, dysarthria, saccadic eye movements, and nystagmus. It is caused by a heterozygous missense variant in the calcium voltage-gated channel subunit alpha1 G (<em>CACNA1G</em>) gene [<a href="#rid174">174,175</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA43</strong>, identified in five generations of a Belgian family, is characterized by gait ataxia, neuropathy, tremor, and hyporeflexia. It is caused by a missense variant in the membrane metalloendopeptidase (<em>MME</em>) gene [<a href="#rid176">176</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA44</strong> was first identified in three generations of an English family. Characteristics include gait ataxia, dysarthria, dysphagia, dysmetria, and dysdiadochokinesia. A case of early-onset disease has also been described. SCA44 is caused by a missense variant in the glutamate metabotropic receptor 1 (<em>GRM1</em>) gene [<a href="#rid177">177</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA45</strong> has been characterized in two generations of a family as a pure cerebellar syndrome with limb and gait ataxia, downbeat nystagmus, and dysarthria. It is caused by a missense variant in the FAT atypical cadherin 2 (<em>FAT2</em>) gene on chromosome 5q [<a href="#rid178">178</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA46</strong>, identified in a Dutch family, is characterized by cerebellar ataxia and sensory neuropathy. Other features include cerebellar dysarthria, nystagmus, jerky pursuit, square-wave jerks, slow saccades, and saccadic dysmetria. It is caused by a phospholipase D family member 3 (<em>PLD3</em>) gene variant [<a href="#rid178">178</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA47</strong> is characterized by gait ataxia, dysmetria, dysarthria, and diplopia. An early-onset form has also been described, manifest by developmental delay, ataxia, chorea, and seizures. It is caused by missense variants in the pumilio RNA-binding family member 1 (<em>PUM1</em>) gene [<a href="#rid179">179</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>SCA48</strong> has been reported in multiple European families with variable degrees of gait ataxia, dysarthria, and dysphagia; deficits in executive function; and psychiatric or affective manifestations, such as depression, anxiety, and apathy. Heterozygous missense, nonsense, or frameshift variants of the STIP1 homology and U-box containing protein 1 (<em>STUB1</em>) gene are seen in affected individuals [<a href="#rid180">180-183</a>].</p><p></p><p class="headingAnchor" id="H15"><span class="h1">OTHER AUTOSOMAL DOMINANT ATAXIAS</span><span class="headingEndMark"> — </span>Other ataxic disorders that may resemble the SCAs include dentatorubral pallidoluysian atrophy (DRPLA), fragile X-associated tremor/ataxia syndrome (FXTAS), and prion disorders.</p><p class="headingAnchor" id="H16"><span class="h2">Dentatorubral pallidoluysian atrophy</span><span class="headingEndMark"> — </span>DRPLA is an autosomal dominant progressive ataxia syndrome caused by cytosine-adenine-guanine (CAG) repeat expansion in the atrophin 1 (<em>ATN1</em>) gene on chromosome 12p.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – DRPLA is a disease that is relatively common in Japan [<a href="#rid184">184</a>]. Most reports suggest that DRPLA is rare in European and North American populations [<a href="#rid185">185-187</a>], but data are conflicting, and one study found it to be an important cause of late-onset cerebellar ataxia in Wales [<a href="#rid188">188</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong> – DRPLA should be suspected when ataxia and rigidity are accompanied by choreoathetosis, myoclonic epilepsy, and dementia [<a href="#rid184">184,189,190</a>]. Other features include hyperreflexia and slowing of saccades. MRI or CT scan often reveals atrophy of the cerebellum and brainstem, calcification of the basal ganglia, and leukodystrophic changes [<a href="#rid191">191</a>].</p><p></p><p class="bulletIndent1">The age of onset varies widely. The mean age of onset in Japan is 47 years [<a href="#rid192">192</a>], while the typical age of onset as reported in Western literature is between 20 and 30 years [<a href="#rid193">193</a>]. Myoclonic epilepsy is common in juvenile (age &lt;20 years) onset. The prevalence of seizures decreases with increasing age beyond 20 years. In adult-onset cases, cerebellar ataxia, choreoathetosis, and dementia are the predominant manifestations, making DRPLA difficult to differentiate from Huntington disease and other hereditary SCAs. (See  <a class="medical medical_review" href="/d/html/4907.html" rel="external">"Huntington disease: Clinical features and diagnosis"</a>.)</p><p></p><p class="bulletIndent1">Haw River syndrome, a variant of DRPLA without the characteristic myoclonic epilepsy, has been described in a few families of African American descent in North Carolina. It is caused by the same expanded repeat as DRPLA [<a href="#rid194">194</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – DRPLA is caused by CAG expansion of 49 to 88 repeats in the <em>ATN1</em> gene on chromosome 12p. The expansion can result in anticipation, especially when transmission is via the father [<a href="#rid189">189,195</a>]. The number of CAG repeats in unaffected subjects is 6 to 35. The product of the <em>ATN1</em> gene is a cytoplasmic protein called atrophin 1 [<a href="#rid196">196</a>]. The action of other enzymes on mutant atrophin 1, such as transglutaminase and caspase, may be involved in the neurotoxicity [<a href="#rid197">197,198</a>].</p><p></p><p class="headingAnchor" id="H18"><span class="h2">Fragile X-associated tremor/ataxia syndrome</span><span class="headingEndMark"> — </span>FXTAS is an adult-onset progressive ataxia syndrome that is seen in some males and females who are carriers of a premutation in the fragile X messenger ribonucleoprotein 1 (<em>FMR1</em>) gene.</p><p class="headingAnchor" id="H4221752012"><span class="h3">Epidemiology</span><span class="headingEndMark"> — </span>Approximately 20 to 33 percent of adult male <em>FMR1</em> premutation carriers display the FXTAS phenotype, and the prevalence of the premutation carrier state is as high as 1 in 813 males, suggesting that FXTAS is a frequent genetic cause of ataxia in older males [<a href="#rid199">199</a>]. Both increasing age and larger cytosine-guanine-guanine (CGG) expansions in premutation carriers are associated with greater motor impairment as assessed by severity of tremor, ataxia, and parkinsonism [<a href="#rid200">200</a>].</p><p>Although FXTAS was initially thought to affect only male premutation carriers, subsequent reports have described the development of FXTAS in females [<a href="#rid201">201,202</a>], related at least in part to X inactivation [<a href="#rid203">203</a>]. Females are less likely than males to develop FXTAS, and those who do have milder disease than males because female premutation carriers are relatively protected from the disease by the presence of a normal X chromosome [<a href="#rid201">201</a>].</p><p class="headingAnchor" id="H1405959396"><span class="h3">Pathogenesis</span><span class="headingEndMark"> — </span>Fragile X syndrome is caused by a trinucleotide CGG expansion of greater than 200 repeats in the <em>FMR1</em> gene, resulting in decreased or absent levels of fragile X messenger ribonucleoprotein (FMRP). It is a common genetic cause of intellectual disability in males [<a href="#rid204">204</a>]. (See  <a class="medical medical_review" href="/d/html/2924.html" rel="external">"Fragile X syndrome: Clinical features and diagnosis in children and adolescents"</a>.)</p><p>FXTAS occurs in carriers of a premutation in the <em>FMR1</em> gene, defined as a CGG expansion ranging from 50 to 200 repeats [<a href="#rid205">205,206</a>]. Carriers of the <em>FMR1</em> gene premutation do not have the more severe neurodevelopmental problems associated with the full variant [<a href="#rid207">207</a>]. However, premutation carriers can present with one or more of the following three clinical syndromes [<a href="#rid208">208</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Premature ovarian failure</p><p class="bulletIndent1"><span class="glyph">●</span>FXTAS</p><p class="bulletIndent1"><span class="glyph">●</span>Mild cognitive and behavioral deficits on the spectrum of those seen in fragile X syndrome</p><p></p><p>The molecular mechanism causing FXTAS differs from that causing the fragile X syndrome. In fragile X syndrome, methylation of DNA (deoxyribonucleic acid) sequences in the promoter where the expanded CGG resides causes silencing of the <em>FMR1</em> gene and complete loss of FMRP. In FXTAS, fragile X RNA is produced, but it is poorly translated into protein. This translational deficit is thought to cause a compensatory increase in the levels of <em>FMR1</em> transcripts. Unfortunately, the RNA bearing the expansion now causes a toxic gain-of-function effect, triggering downstream protein accumulation and neurodegeneration [<a href="#rid207">207</a>].</p><p class="headingAnchor" id="H1719237737"><span class="h3">Clinical features</span><span class="headingEndMark"> — </span>The predominant clinical feature of FXTAS is a late-onset ataxia associated with postural tremor [<a href="#rid205">205,209,210</a>]. Additional clinical features can include short-term memory loss, executive function deficits, cognitive decline, parkinsonism, peripheral neuropathy, lower limb proximal muscle weakness, and autonomic dysfunction [<a href="#rid207">207,211</a>].</p><p>Brain atrophy and characteristic high-signal lesions in the middle cerebellar peduncle and splenium of the corpus callosum can be seen with brain MRI using T2 and fluid-attenuated inversion recovery (FLAIR) sequences [<a href="#rid205">205,212,213</a>]. On neuropathologic examination, findings include white matter disease associated with astrocytic pathology, intranuclear inclusions in both neurons and astrocytes in brain and spinal cord, amyloid beta within capillaries, and cerebral microbleeds [<a href="#rid214">214,215</a>].</p><p>Misdiagnosis of FXTAS may be common. This point is illustrated by a study of 56 patients with FXTAS and a family history of fragile X syndrome [<a href="#rid216">216</a>]. These patients received a wide variety of prior diagnoses other than FXTAS as an explanation for their symptoms, including various types of parkinsonism, tremor, ataxia, dementia, and cerebrovascular disease.</p><p class="headingAnchor" id="H20"><span class="h3"><i>FMR1</i> DNA testing</span><span class="headingEndMark"> — </span>Based on proposed guidelines for genetic confirmation of FXTAS, testing for <em>FMR1</em> is suggested for patients who have either of the following presentations [<a href="#rid216">216,217</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Unexplained cerebellar ataxia in males older than age 50</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Presence of action tremor, parkinsonism, or dementia in males older than age 50 with either a family history of developmental delay, autism, intellectual disability, or premature ovarian failure, or the middle cerebellar peduncle sign on brain MRI</p><p></p><p>Screening for the <em>FMR1</em> premutation in patients who have neurologic illnesses, such as Parkinson disease [<a href="#rid218">218</a>], essential tremor [<a href="#rid219">219</a>], or multiple system atrophy [<a href="#rid220">220</a>], has a very low yield. Screening in older males with late-onset cerebellar ataxia may be more fruitful [<a href="#rid199">199</a>].</p><p class="headingAnchor" id="H21"><span class="h2">Gerstmann-Sträussler-Scheinker syndrome</span><span class="headingEndMark"> — </span>The prion diseases, particularly the ataxic variant of the Gerstmann-Sträussler-Scheinker syndrome (GSS), can mimic SCA.</p><p>GSS is a genetic prion disease inherited in an autosomal dominant pattern and caused by pathogenic variants in the prion protein (<em>PRNP</em>) gene. GSS is discussed separately. (See  <a class="medical medical_review" href="/d/html/5074.html" rel="external">"Diseases of the central nervous system caused by prions", section on 'Gerstmann-Sträussler-Scheinker syndrome'</a>.)</p><p class="headingAnchor" id="H1341201660"><span class="h2">Others</span><span class="headingEndMark"> — </span>The International Parkinson and Movement Disorder Society (MDS) classification for hereditary movement disorders includes a number of additional autosomal dominant forms of hereditary ataxia with the ATX prefix [<a href="#rid1">1</a>]. Some of these have already been named as SCA types (eg, SCA13, SCA34, SCA37, SCA40, SCA42, and SCA47). Others without an SCA designation continue to be added and are listed in the table  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H99235102"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition</strong> – The spinocerebellar ataxias (SCAs) are a genetically and clinically heterogeneous group of autosomal dominant neurodegenerative disorders characterized by a slowly progressive cerebellar syndrome in association with various other neurologic features that vary with the affected gene. Most are adult-onset syndromes, although childhood forms exist. (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nomenclature</strong> – The SCAs are classified according to the genetic loci and numbered according to their order of identification: SCA1 through SCA48 (and the number continues to grow)  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>). (See <a class="local">'Nomenclature and classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical spectrum</strong> – Progressive ataxia and other signs of cerebellar dysfunction are a feature of each type of SCA. Other distinguishing features may suggest a particular type of SCA  (<a class="graphic graphic_table graphicRef74269" href="/d/graphic/74269.html" rel="external">table 1</a>). (See <a class="local">'Clinical spectrum'</a> above and <a class="local">'Specific disorders'</a> above.)</p><p></p><p class="bulletIndent1">The four most common SCAs are SCA1, SCA2, SCA3, and SCA6. In these disorders, symptoms typically begin in middle age, and most patients require a wheelchair by 10 to 15 years after symptom onset due to the degree of ataxia.</p><p></p><p class="bulletIndent1">No disease-modifying treatments are available, but a number of strategies are under investigation in animal models and early-stage human trials. (See <a class="local">'Prognosis'</a> above and <a class="local">'Treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – Genetic testing is the most efficient and definitive way to determine the cause of the symptoms and to identify the ataxia subtype in a patient with suspected SCA based on clinical features and family history. In most cases, an SCA repeat expansion gene panel is the most appropriate first test.</p><p></p><p class="bulletIndent1">Approximately 60 to 75 percent of patients with SCA have variants in the known loci. Among patients with apparently idiopathic sporadic cerebellar ataxia (ie, no family history), an SCA variant (most often SCA6) or Friedreich ataxia can be identified in approximately 20 percent. (See <a class="local">'Diagnostic evaluation'</a> above.)</p><p></p><p class="bulletIndent1">Other genetic ataxic disorders that may resemble SCA include fragile X-associated tremor/ataxia syndrome (FXTAS), dentatorubral pallidoluysian atrophy (DRPLA), and prion disorders, particularly the rare ataxic variant of the Gerstmann-Sträussler-Scheinker syndrome (GSS). (See <a class="local">'Other autosomal dominant ataxias'</a> above.)</p><p></p><p class="bulletIndent1">The etiologic evaluation of a patient with ataxia more generally is reviewed separately. (See  <a class="medical medical_review" href="/d/html/14134.html" rel="external">"Overview of cerebellar ataxia in adults", section on 'Etiologic evaluation'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pathogenesis</strong> – Several types of SCAs (SCA1, SCA2, SCA3, SCA6, SCA7, SCA12, SCA17) and DRPLA are associated with expansion of cytosine-adenine-guanine (CAG) repeats in the region that encodes for polyglutamine tracts in the protein products. The age of onset and rate of disability progression vary according to individual differences in the length of the causative CAG trinucleotide repeat. (See <a class="local">'CAG repeat disorders'</a> above.)</p><p></p><p class="bulletIndent1">Pathogenesis of other SCAs is variable and reviewed individually. (See <a class="local">'Specific disorders'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Lange LM, Gonzalez-Latapi P, Rajalingam R, et al. Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update. Mov Disord 2022; 37:905.</a></li><li><a class="nounderline abstract_t">Manto MU. The wide spectrum of spinocerebellar ataxias (SCAs). Cerebellum 2005; 4:2.</a></li><li><a class="nounderline abstract_t">Schöls L, Szymanski S, Peters S, et al. Genetic background of apparently idiopathic sporadic cerebellar ataxia. Hum Genet 2000; 107:132.</a></li><li><a class="nounderline abstract_t">Trottier Y, Lutz Y, Stevanin G, et al. Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature 1995; 378:403.</a></li><li><a class="nounderline abstract_t">Jacobi H, Bauer P, Giunti P, et al. The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study. Neurology 2011; 77:1035.</a></li><li><a class="nounderline abstract_t">Rüb U, Bürk K, Schöls L, et al. Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3. Neurology 2004; 63:1258.</a></li><li><a class="nounderline abstract_t">Ibañez K, Polke J, Hagelstrom RT, et al. Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study. Lancet Neurol 2022; 21:234.</a></li><li><a class="nounderline abstract_t">Guerrini L, Lolli F, Ginestroni A, et al. Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study. Brain 2004; 127:1785.</a></li><li><a class="nounderline abstract_t">Klockgether T, Lüdtke R, Kramer B, et al. The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain 1998; 121 ( Pt 4):589.</a></li><li><a class="nounderline abstract_t">Diallo A, Jacobi H, Cook A, et al. Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study. Lancet Neurol 2018; 17:327.</a></li><li><a class="nounderline abstract_t">Jacobi H, du Montcel ST, Romanzetti S, et al. Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study. Lancet Neurol 2020; 19:738.</a></li><li class="breakAll">Bird TD. Hereditary ataxia overview. GeneReviews. Available at: www.ncbi.nlm.nih.gov/bookshelf/br.fcgi?book=gene&amp;part=ataxias (Accessed on September 29, 2011).</li><li><a class="nounderline abstract_t">Sullivan R, Yau WY, O'Connor E, Houlden H. Spinocerebellar ataxia: an update. J Neurol 2019; 266:533.</a></li><li><a class="nounderline abstract_t">Tang B, Liu C, Shen L, et al. Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds. Arch Neurol 2000; 57:540.</a></li><li><a class="nounderline abstract_t">Geschwind DH, Perlman S, Figueroa CP, et al. The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia. Am J Hum Genet 1997; 60:842.</a></li><li><a class="nounderline abstract_t">Moseley ML, Benzow KA, Schut LJ, et al. Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families. Neurology 1998; 51:1666.</a></li><li><a class="nounderline abstract_t">Storey E, du Sart D, Shaw JH, et al. Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia. Am J Med Genet 2000; 95:351.</a></li><li><a class="nounderline abstract_t">Ranum LP, Lundgren JK, Schut LJ, et al. Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia. Am J Hum Genet 1995; 57:603.</a></li><li><a class="nounderline abstract_t">Orr HT, Zoghbi HY. Trinucleotide repeat disorders. Annu Rev Neurosci 2007; 30:575.</a></li><li><a class="nounderline abstract_t">Orr HT, Chung MY, Banfi S, et al. Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1. Nat Genet 1993; 4:221.</a></li><li><a class="nounderline abstract_t">Skinner PJ, Koshy BT, Cummings CJ, et al. Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures. Nature 1997; 389:971.</a></li><li><a class="nounderline abstract_t">Klement IA, Skinner PJ, Kaytor MD, et al. Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice. Cell 1998; 95:41.</a></li><li><a class="nounderline abstract_t">Zoghbi HY, Orr HT. Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1. J Biol Chem 2009; 284:7425.</a></li><li><a class="nounderline abstract_t">de Chiara C, Giannini C, Adinolfi S, et al. The AXH module: an independently folded domain common to ataxin-1 and HBP1. FEBS Lett 2003; 551:107.</a></li><li><a class="nounderline abstract_t">Gehrking KM, Andresen JM, Duvick L, et al. Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model. Hum Mol Genet 2011; 20:2204.</a></li><li><a class="nounderline abstract_t">Lam YC, Bowman AB, Jafar-Nejad P, et al. ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology. Cell 2006; 127:1335.</a></li><li><a class="nounderline abstract_t">Emamian ES, Kaytor MD, Duvick LA, et al. Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice. Neuron 2003; 38:375.</a></li><li><a class="nounderline abstract_t">Lim J, Crespo-Barreto J, Jafar-Nejad P, et al. Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1. Nature 2008; 452:713.</a></li><li><a class="nounderline abstract_t">Orr HT. SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis. Prog Neurobiol 2012; 99:179.</a></li><li><a class="nounderline abstract_t">Rousseaux MWC, Tschumperlin T, Lu HC, et al. ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism. Neuron 2018; 97:1235.</a></li><li><a class="nounderline abstract_t">Jafar-Nejad P, Ward CS, Richman R, et al. Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration. Proc Natl Acad Sci U S A 2011; 108:2142.</a></li><li><a class="nounderline abstract_t">Park J, Al-Ramahi I, Tan Q, et al. RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1. Nature 2013; 498:325.</a></li><li><a class="nounderline abstract_t">Friedrich J, Kordasiewicz HB, O'Callaghan B, et al. Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles. JCI Insight 2018; 3.</a></li><li><a class="nounderline abstract_t">Nitschke L, Tewari A, Coffin SL, et al. miR760 regulates ATXN1 levels via interaction with its 5' untranslated region. Genes Dev 2020; 34:1147.</a></li><li><a class="nounderline abstract_t">Lorenzetti D, Bohlega S, Zoghbi HY. The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia. Neurology 1997; 49:1009.</a></li><li><a class="nounderline abstract_t">Orozco Diaz G, Nodarse Fleites A, Cordovés Sagaz R, Auburger G. Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba. Neurology 1990; 40:1369.</a></li><li><a class="nounderline abstract_t">Pulst SM, Nechiporuk A, Nechiporuk T, et al. Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2. Nat Genet 1996; 14:269.</a></li><li><a class="nounderline abstract_t">Sanpei K, Takano H, Igarashi S, et al. Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT. Nat Genet 1996; 14:277.</a></li><li><a class="nounderline abstract_t">Huynh DP, Figueroa K, Hoang N, Pulst SM. Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human. Nat Genet 2000; 26:44.</a></li><li><a class="nounderline abstract_t">Imbert G, Saudou F, Yvert G, et al. Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet 1996; 14:285.</a></li><li><a class="nounderline abstract_t">Velázquez-Pérez L, Seifried C, Santos-Falcón N, et al. Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol 2004; 56:444.</a></li><li><a class="nounderline abstract_t">Paciorkowski AR, Shafrir Y, Hrivnak J, et al. Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms. Neurology 2011; 77:1055.</a></li><li><a class="nounderline abstract_t">Singh A, Faruq M, Mukerji M, et al. Infantile onset spinocerebellar ataxia 2 (SCA2): a clinical report with review of previous cases. J Child Neurol 2014; 29:139.</a></li><li><a class="nounderline abstract_t">Fernandez M, McClain ME, Martinez RA, et al. Late-onset SCA2: 33 CAG repeats are sufficient to cause disease. Neurology 2000; 55:569.</a></li><li><a class="nounderline abstract_t">Gwinn-Hardy K, Chen JY, Liu HC, et al. Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese. Neurology 2000; 55:800.</a></li><li><a class="nounderline abstract_t">Babovic-Vuksanovic D, Snow K, Patterson MC, Michels VV. Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion. Am J Med Genet 1998; 79:383.</a></li><li><a class="nounderline abstract_t">Malandrini A, Galli L, Villanova M, et al. CAG repeat expansion in an italian family with spinocerebellar ataxia type 2 (SCA2): a clinical and genetic study. Eur Neurol 1998; 40:164.</a></li><li><a class="nounderline abstract_t">Belal S, Cancel G, Stevanin G, et al. Clinical and genetic analysis of a Tunisian family with autosomal dominant cerebellar ataxia type 1 linked to the SCA2 locus. Neurology 1994; 44:1423.</a></li><li><a class="nounderline abstract_t">Dürr A, Smadja D, Cancel G, et al. Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families. Brain 1995; 118 ( Pt 6):1573.</a></li><li><a class="nounderline abstract_t">França MC Jr, D'Abreu A, Nucci A, Lopes-Cendes I. Muscle excitability abnormalities in Machado-Joseph disease. Arch Neurol 2008; 65:525.</a></li><li><a class="nounderline abstract_t">Kawai Y, Takeda A, Abe Y, et al. Cognitive impairments in Machado-Joseph disease. Arch Neurol 2004; 61:1757.</a></li><li><a class="nounderline abstract_t">Yeh TH, Lu CS, Chou YH, et al. Autonomic dysfunction in Machado-Joseph disease. Arch Neurol 2005; 62:630.</a></li><li><a class="nounderline abstract_t">Pedroso JL, França MC Jr, Braga-Neto P, et al. Nonmotor and extracerebellar features in Machado-Joseph disease: a review. Mov Disord 2013; 28:1200.</a></li><li><a class="nounderline abstract_t">D'Abreu A, França M Jr, Conz L, et al. Sleep symptoms and their clinical correlates in Machado-Joseph disease. Acta Neurol Scand 2009; 119:277.</a></li><li><a class="nounderline abstract_t">Kawaguchi Y, Okamoto T, Taniwaki M, et al. CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1. Nat Genet 1994; 8:221.</a></li><li><a class="nounderline abstract_t">Higgins JJ, Nee LE, Vasconcelos O, et al. Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease. Neurology 1996; 46:208.</a></li><li><a class="nounderline abstract_t">Tait D, Riccio M, Sittler A, et al. Ataxin-3 is transported into the nucleus and associates with the nuclear matrix. Hum Mol Genet 1998; 7:991.</a></li><li><a class="nounderline abstract_t">Warrick JM, Paulson HL, Gray-Board GL, et al. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila. Cell 1998; 93:939.</a></li><li><a class="nounderline abstract_t">Ikeda H, Yamaguchi M, Sugai S, et al. Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo. Nat Genet 1996; 13:196.</a></li><li><a class="nounderline abstract_t">Leotti VB, de Vries JJ, Oliveira CM, et al. CAG Repeat Size Influences the Progression Rate of Spinocerebellar Ataxia Type 3. Ann Neurol 2021; 89:66.</a></li><li><a class="nounderline abstract_t">Flanigan K, Gardner K, Alderson K, et al. Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1. Am J Hum Genet 1996; 59:392.</a></li><li><a class="nounderline abstract_t">Nagaoka U, Takashima M, Ishikawa K, et al. A gene on SCA4 locus causes dominantly inherited pure cerebellar ataxia. Neurology 2000; 54:1971.</a></li><li><a class="nounderline abstract_t">Stevanin G, Herman A, Brice A, Dürr A. Clinical and MRI findings in spinocerebellar ataxia type 5. Neurology 1999; 53:1355.</a></li><li><a class="nounderline abstract_t">Jacob FD, Ho ES, Martinez-Ojeda M, et al. Case of infantile onset spinocerebellar ataxia type 5. J Child Neurol 2013; 28:1292.</a></li><li><a class="nounderline abstract_t">Ranum LP, Schut LJ, Lundgren JK, et al. Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11. Nat Genet 1994; 8:280.</a></li><li><a class="nounderline abstract_t">Ikeda Y, Dick KA, Weatherspoon MR, et al. Spectrin mutations cause spinocerebellar ataxia type 5. Nat Genet 2006; 38:184.</a></li><li><a class="nounderline abstract_t">Craig K, Keers SM, Archibald K, et al. Molecular epidemiology of spinocerebellar ataxia type 6. Ann Neurol 2004; 55:752.</a></li><li><a class="nounderline abstract_t">Gomez CM, Thompson RM, Gammack JT, et al. Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset. Ann Neurol 1997; 42:933.</a></li><li><a class="nounderline abstract_t">Stevanin G, Dürr A, David G, et al. Clinical and molecular features of spinocerebellar ataxia type 6. Neurology 1997; 49:1243.</a></li><li><a class="nounderline abstract_t">Matsumura R, Futamura N, Fujimoto Y, et al. Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the CAG repeat expansion. Neurology 1997; 49:1238.</a></li><li><a class="nounderline abstract_t">Zhuchenko O, Bailey J, Bonnen P, et al. Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel. Nat Genet 1997; 15:62.</a></li><li><a class="nounderline abstract_t">Restituito S, Thompson RM, Eliet J, et al. The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes. J Neurosci 2000; 20:6394.</a></li><li><a class="nounderline abstract_t">Ishikawa K, Fujigasaki H, Saegusa H, et al. Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6. Hum Mol Genet 1999; 8:1185.</a></li><li><a class="nounderline abstract_t">Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.</a></li><li><a class="nounderline abstract_t">Terwindt GM, Ophoff RA, Haan J, et al. Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group. Neurology 1998; 50:1105.</a></li><li><a class="nounderline abstract_t">Benton CS, de Silva R, Rutledge SL, et al. Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype. Neurology 1998; 51:1081.</a></li><li><a class="nounderline abstract_t">Ansorge O, Giunti P, Michalik A, et al. Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats. Ann Neurol 2004; 56:448.</a></li><li><a class="nounderline abstract_t">Gouw LG, Kaplan CD, Haines JH, et al. Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p. Nat Genet 1995; 10:89.</a></li><li><a class="nounderline abstract_t">David G, Abbas N, Stevanin G, et al. Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet 1997; 17:65.</a></li><li><a class="nounderline abstract_t">Stevanin G, Giunti P, Belal GD, et al. De novo expansion of intermediate alleles in spinocerebellar ataxia 7. Hum Mol Genet 1998; 7:1809.</a></li><li><a class="nounderline abstract_t">Lindenberg KS, Yvert G, Müller K, Landwehrmeyer GB. Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation. Brain Pathol 2000; 10:385.</a></li><li><a class="nounderline abstract_t">Yvert G, Lindenberg KS, Picaud S, et al. Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice. Hum Mol Genet 2000; 9:2491.</a></li><li><a class="nounderline abstract_t">Schöls L, Bauer P, Schmidt T, et al. Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis. Lancet Neurol 2004; 3:291.</a></li><li><a class="nounderline abstract_t">Day JW, Schut LJ, Moseley ML, et al. Spinocerebellar ataxia type 8: clinical features in a large family. Neurology 2000; 55:649.</a></li><li><a class="nounderline abstract_t">Juvonen V, Hietala M, Päivärinta M, et al. Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion. Ann Neurol 2000; 48:354.</a></li><li><a class="nounderline abstract_t">Ito H, Kawakami H, Wate R, et al. Clinicopathologic investigation of a family with expanded SCA8 CTA/CTG repeats. Neurology 2006; 67:1479.</a></li><li><a class="nounderline abstract_t">Todd PK, Paulson HL. RNA-mediated neurodegeneration in repeat expansion disorders. Ann Neurol 2010; 67:291.</a></li><li><a class="nounderline abstract_t">Koob MD, Moseley ML, Schut LJ, et al. An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8). Nat Genet 1999; 21:379.</a></li><li><a class="nounderline abstract_t">Silveira I, Alonso I, Guimarães L, et al. High germinal instability of the (CTG)n at the SCA8 locus of both expanded and normal alleles. Am J Hum Genet 2000; 66:830.</a></li><li><a class="nounderline abstract_t">Moseley ML, Zu T, Ikeda Y, et al. Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8. Nat Genet 2006; 38:758.</a></li><li><a class="nounderline abstract_t">Ikeda Y, Dalton JC, Moseley ML, et al. Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia. Am J Hum Genet 2004; 75:3.</a></li><li><a class="nounderline abstract_t">Grewal RP, Achari M, Matsuura T, et al. Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10. Arch Neurol 2002; 59:1285.</a></li><li><a class="nounderline abstract_t">Teive HA, Roa BB, Raskin S, et al. Clinical phenotype of Brazilian families with spinocerebellar ataxia 10. Neurology 2004; 63:1509.</a></li><li><a class="nounderline abstract_t">Gatto EM, Gao R, White MC, et al. Ethnic origin and extrapyramidal signs in an Argentinean spinocerebellar ataxia type 10 family. Neurology 2007; 69:216.</a></li><li><a class="nounderline abstract_t">Matsuura T, Achari M, Khajavi M, et al. Mapping of the gene for a novel spinocerebellar ataxia with pure cerebellar signs and epilepsy. Ann Neurol 1999; 45:407.</a></li><li><a class="nounderline abstract_t">Zu L, Figueroa KP, Grewal R, Pulst SM. Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22. Am J Hum Genet 1999; 64:594.</a></li><li><a class="nounderline abstract_t">Matsuura T, Yamagata T, Burgess DL, et al. Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10. Nat Genet 2000; 26:191.</a></li><li><a class="nounderline abstract_t">Worth PF, Giunti P, Gardner-Thorpe C, et al. Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3. Am J Hum Genet 1999; 65:420.</a></li><li><a class="nounderline abstract_t">Houlden H, Johnson J, Gardner-Thorpe C, et al. Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11. Nat Genet 2007; 39:1434.</a></li><li><a class="nounderline abstract_t">Holmes SE, O'Hearn EE, McInnis MG, et al. Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12. Nat Genet 1999; 23:391.</a></li><li><a class="nounderline abstract_t">Srivastava AK, Takkar A, Garg A, Faruq M. Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B. Brain 2017; 140:27.</a></li><li><a class="nounderline abstract_t">Herman-Bert A, Stevanin G, Netter JC, et al. Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation. Am J Hum Genet 2000; 67:229.</a></li><li><a class="nounderline abstract_t">Waters MF, Minassian NA, Stevanin G, et al. Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes. Nat Genet 2006; 38:447.</a></li><li><a class="nounderline abstract_t">Yamashita I, Sasaki H, Yabe I, et al. A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter. Ann Neurol 2000; 48:156.</a></li><li><a class="nounderline abstract_t">Yabe I, Sasaki H, Chen DH, et al. Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma. Arch Neurol 2003; 60:1749.</a></li><li><a class="nounderline abstract_t">Verbeek DS, Knight MA, Harmison GG, et al. Protein kinase C gamma mutations in spinocerebellar ataxia 14 increase kinase activity and alter membrane targeting. Brain 2005; 128:436.</a></li><li><a class="nounderline abstract_t">Chen DH, Cimino PJ, Ranum LP, et al. The clinical and genetic spectrum of spinocerebellar ataxia 14. Neurology 2005; 64:1258.</a></li><li><a class="nounderline abstract_t">Klebe S, Durr A, Rentschler A, et al. New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14. Ann Neurol 2005; 58:720.</a></li><li><a class="nounderline abstract_t">Storey E, Gardner RJ, Knight MA, et al. A new autosomal dominant pure cerebellar ataxia. Neurology 2001; 57:1913.</a></li><li><a class="nounderline abstract_t">Miyoshi Y, Yamada T, Tanimura M, et al. A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1-24.1. Neurology 2001; 57:96.</a></li><li><a class="nounderline abstract_t">Knight MA, Kennerson ML, Anney RJ, et al. Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter: exclusion of the ITPR1 gene, the human orthologue of an ataxic mouse mutant. Neurobiol Dis 2003; 13:147.</a></li><li><a class="nounderline abstract_t">Hara K, Fukushima T, Suzuki T, et al. Japanese SCA families with an unusual phenotype linked to a locus overlapping with SCA15 locus. Neurology 2004; 62:648.</a></li><li><a class="nounderline abstract_t">van de Leemput J, Chandran J, Knight MA, et al. Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans. PLoS Genet 2007; 3:e108.</a></li><li><a class="nounderline abstract_t">Hara K, Shiga A, Nozaki H, et al. Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families. Neurology 2008; 71:547.</a></li><li><a class="nounderline abstract_t">Iwaki A, Kawano Y, Miura S, et al. Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16. J Med Genet 2008; 45:32.</a></li><li><a class="nounderline abstract_t">Gardner RJ. "SCA16" is really SCA15. J Med Genet 2008; 45:192.</a></li><li><a class="nounderline abstract_t">Miura S, Shibata H, Furuya H, et al. The contactin 4 gene locus at 3p26 is a candidate gene of SCA16. Neurology 2006; 67:1236.</a></li><li><a class="nounderline abstract_t">Nakamura K, Jeong SY, Uchihara T, et al. SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein. Hum Mol Genet 2001; 10:1441.</a></li><li><a class="nounderline abstract_t">Rossi M, Hamed M, Rodríguez-Antigüedad J, et al. Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review. Mov Disord 2023; 38:368.</a></li><li><a class="nounderline abstract_t">Schneider SA, van de Warrenburg BP, Hughes TD, et al. Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family. Neurology 2006; 67:1701.</a></li><li><a class="nounderline abstract_t">Friedman MJ, Shah AG, Fang ZH, et al. Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration. Nat Neurosci 2007; 10:1519.</a></li><li><a class="nounderline abstract_t">Brkanac Z, Fernandez M, Matsushita M, et al. Autosomal dominant sensory/motor neuropathy with Ataxia (SMNA): Linkage to chromosome 7q22-q32. Am J Med Genet 2002; 114:450.</a></li><li><a class="nounderline abstract_t">Schelhaas HJ, Ippel PF, Hageman G, et al. Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia. J Neurol 2001; 248:113.</a></li><li><a class="nounderline abstract_t">Verbeek DS, Schelhaas JH, Ippel EF, et al. Identification of a novel SCA locus ( SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21. Hum Genet 2002; 111:388.</a></li><li><a class="nounderline abstract_t">Chung MY, Lu YC, Cheng NC, Soong BW. A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23. Brain 2003; 126:1293.</a></li><li><a class="nounderline abstract_t">Duarri A, Jezierska J, Fokkens M, et al. Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19. Ann Neurol 2012; 72:870.</a></li><li><a class="nounderline abstract_t">Lee YC, Durr A, Majczenko K, et al. Mutations in KCND3 cause spinocerebellar ataxia type 22. Ann Neurol 2012; 72:859.</a></li><li><a class="nounderline abstract_t">Pulst SM, Otis TS. Repolarization matters: mutations in the Kv4.3 potassium channel cause SCA19/22. Ann Neurol 2012; 72:829.</a></li><li><a class="nounderline abstract_t">Knight MA, Gardner RJ, Bahlo M, et al. Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20. Brain 2004; 127:1172.</a></li><li><a class="nounderline abstract_t">Knight MA, Hernandez D, Diede SJ, et al. A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20. Hum Mol Genet 2008; 17:3847.</a></li><li><a class="nounderline abstract_t">Devos D, Schraen-Maschke S, Vuillaume I, et al. Clinical features and genetic analysis of a new form of spinocerebellar ataxia. Neurology 2001; 56:234.</a></li><li><a class="nounderline abstract_t">Delplanque J, Devos D, Huin V, et al. TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment. Brain 2014; 137:2657.</a></li><li><a class="nounderline abstract_t">Burdekin ED, Fogel BL, Jeste SS, et al. The Neurodevelopmental and Motor Phenotype of SCA21 (ATX-TMEM240). J Child Neurol 2020; 35:953.</a></li><li><a class="nounderline abstract_t">Verbeek DS, van de Warrenburg BP, Wesseling P, et al. Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3. Brain 2004; 127:2551.</a></li><li><a class="nounderline abstract_t">Bakalkin G, Watanabe H, Jezierska J, et al. Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23. Am J Hum Genet 2010; 87:593.</a></li><li><a class="nounderline abstract_t">Swartz BE, Burmeister M, Somers JT, et al. A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus. Ann N Y Acad Sci 2002; 956:441.</a></li><li><a class="nounderline abstract_t">Swartz BE, Li S, Bespalova I, et al. Pathogenesis of clinical signs in recessive ataxia with saccadic intrusions. Ann Neurol 2003; 54:824.</a></li><li><a class="nounderline abstract_t">Stevanin G, Bouslam N, Thobois S, et al. Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p. Ann Neurol 2004; 55:97.</a></li><li><a class="nounderline abstract_t">Yu GY, Howell MJ, Roller MJ, et al. Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6. Ann Neurol 2005; 57:349.</a></li><li><a class="nounderline abstract_t">Hekman KE, Yu GY, Brown CD, et al. A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult. Hum Mol Genet 2012; 21:5472.</a></li><li><a class="nounderline abstract_t">van Swieten JC, Brusse E, de Graaf BM, et al. A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected]. Am J Hum Genet 2003; 72:191.</a></li><li><a class="nounderline abstract_t">Brusse E, de Koning I, Maat-Kievit A, et al. Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype. Mov Disord 2006; 21:396.</a></li><li><a class="nounderline abstract_t">Dalski A, Atici J, Kreuz FR, et al. Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias. Eur J Hum Genet 2005; 13:118.</a></li><li><a class="nounderline abstract_t">Pellerin D, Danzi MC, Wilke C, et al. Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia. N Engl J Med 2023; 388:128.</a></li><li><a class="nounderline abstract_t">Rafehi H, Read J, Szmulewicz DJ, et al. An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14. Am J Hum Genet 2023; 110:1018.</a></li><li><a class="nounderline abstract_t">Wirth T, Clément G, Delvallée C, et al. Natural History and Phenotypic Spectrum of GAA-FGF14 Sporadic Late-Onset Cerebellar Ataxia (SCA27B). Mov Disord 2023; 38:1950.</a></li><li><a class="nounderline abstract_t">Zeng YH, Gan SR, Chen WJ. Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia. N Engl J Med 2023; 388:e70.</a></li><li><a class="nounderline abstract_t">Pellerin D, Wilke C, Traschütz A, et al. Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy. J Neurol Neurosurg Psychiatry 2024; 95:175.</a></li><li><a class="nounderline abstract_t">Wilke C, Pellerin D, Mengel D, et al. GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response. Brain 2023; 146:4144.</a></li><li><a class="nounderline abstract_t">Cagnoli C, Mariotti C, Taroni F, et al. SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22-q11.2. Brain 2006; 129:235.</a></li><li><a class="nounderline abstract_t">Di Bella D, Lazzaro F, Brusco A, et al. Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28. Nat Genet 2010; 42:313.</a></li><li><a class="nounderline abstract_t">Dudding TE, Friend K, Schofield PW, et al. Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus. Neurology 2004; 63:2288.</a></li><li><a class="nounderline abstract_t">Ishikawa K, Toru S, Tsunemi T, et al. An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains. Am J Hum Genet 2005; 77:280.</a></li><li><a class="nounderline abstract_t">Owada K, Ishikawa K, Toru S, et al. A clinical, genetic, and neuropathologic study in a family with 16q-linked ADCA type III. Neurology 2005; 65:629.</a></li><li><a class="nounderline abstract_t">Onodera Y, Aoki M, Mizuno H, et al. Clinical features of chromosome 16q22.1 linked autosomal dominant cerebellar ataxia in Japanese. Neurology 2006; 67:1300.</a></li><li><a class="nounderline abstract_t">Sato N, Amino T, Kobayashi K, et al. Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n. Am J Hum Genet 2009; 85:544.</a></li><li><a class="nounderline abstract_t">Jiang H, Zhu HP, Gomez CM. SCA32: an autosomal dominant cerebellar ataxia with azoospermia maps to chromosome 7q32-q33 [abstract]. Mov Disord 2010; 25:S192.</a></li><li><a class="nounderline abstract_t">Giroux JM, Barbeau A. Erythrokeratodermia with ataxia. Arch Dermatol 1972; 106:183.</a></li><li><a class="nounderline abstract_t">Cadieux-Dion M, Turcotte-Gauthier M, Noreau A, et al. Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia. JAMA Neurol 2014; 71:470.</a></li><li><a class="nounderline abstract_t">Ozaki K, Doi H, Mitsui J, et al. A Novel Mutation in ELOVL4 Leading to Spinocerebellar Ataxia (SCA) With the Hot Cross Bun Sign but Lacking Erythrokeratodermia: A Broadened Spectrum of SCA34. JAMA Neurol 2015; 72:797.</a></li><li><a class="nounderline abstract_t">Wang JL, Yang X, Xia K, et al. TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing. Brain 2010; 133:3510.</a></li><li><a class="nounderline abstract_t">Li M, Pang SY, Song Y, et al. Whole exome sequencing identifies a novel mutation in the transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family. Clin Genet 2013; 83:269.</a></li><li><a class="nounderline abstract_t">Guo YC, Lin JJ, Liao YC, et al. Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical and genetic characterization. Neurology 2014; 83:1554.</a></li><li><a class="nounderline abstract_t">Kobayashi H, Abe K, Matsuura T, et al. Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement. Am J Hum Genet 2011; 89:121.</a></li><li><a class="nounderline abstract_t">Ikeda Y, Ohta Y, Kobayashi H, et al. Clinical features of SCA36: a novel spinocerebellar ataxia with motor neuron involvement (Asidan). Neurology 2012; 79:333.</a></li><li><a class="nounderline abstract_t">Sugihara K, Maruyama H, Morino H, et al. The clinical characteristics of spinocerebellar ataxia 36: a study of 2121 Japanese ataxia patients. Mov Disord 2012; 27:1158.</a></li><li><a class="nounderline abstract_t">García-Murias M, Quintáns B, Arias M, et al. 'Costa da Morte' ataxia is spinocerebellar ataxia 36: clinical and genetic characterization. Brain 2012; 135:1423.</a></li><li><a class="nounderline abstract_t">Obayashi M, Stevanin G, Synofzik M, et al. Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion. J Neurol Neurosurg Psychiatry 2015; 86:986.</a></li><li><a class="nounderline abstract_t">Serrano-Munuera C, Corral-Juan M, Stevanin G, et al. New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32. JAMA Neurol 2013; 70:764.</a></li><li><a class="nounderline abstract_t">Corral-Juan M, Serrano-Munuera C, Rábano A, et al. Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37. Brain 2018; 141:1981.</a></li><li><a class="nounderline abstract_t">Di Gregorio E, Borroni B, Giorgio E, et al. ELOVL5 mutations cause spinocerebellar ataxia 38. Am J Hum Genet 2014; 95:209.</a></li><li><a class="nounderline abstract_t">Tsoi H, Yu AC, Chen ZS, et al. A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia. J Med Genet 2014; 51:590.</a></li><li><a class="nounderline abstract_t">Fogel BL, Hanson SM, Becker EB. Do mutations in the murine ataxia gene TRPC3 cause cerebellar ataxia in humans? Mov Disord 2015; 30:284.</a></li><li><a class="nounderline abstract_t">Coutelier M, Blesneac I, Monteil A, et al. A Recurrent Mutation in CACNA1G Alters Cav3.1 T-Type Calcium-Channel Conduction and Causes Autosomal-Dominant Cerebellar Ataxia. Am J Hum Genet 2015; 97:726.</a></li><li><a class="nounderline abstract_t">Morino H, Matsuda Y, Muguruma K, et al. A mutation in the low voltage-gated calcium channel CACNA1G alters the physiological properties of the channel, causing spinocerebellar ataxia. Mol Brain 2015; 8:89.</a></li><li><a class="nounderline abstract_t">Depondt C, Donatello S, Rai M, et al. MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43). Neurol Genet 2016; 2:e94.</a></li><li><a class="nounderline abstract_t">Watson LM, Bamber E, Schnekenberg RP, et al. Dominant Mutations in GRM1 Cause Spinocerebellar Ataxia Type 44. Am J Hum Genet 2017; 101:451.</a></li><li><a class="nounderline abstract_t">Nibbeling EAR, Duarri A, Verschuuren-Bemelmans CC, et al. Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia. Brain 2017; 140:2860.</a></li><li><a class="nounderline abstract_t">Gennarino VA, Palmer EE, McDonell LM, et al. A Mild PUM1 Mutation Is Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and Seizures. Cell 2018; 172:924.</a></li><li><a class="nounderline abstract_t">De Michele G, Lieto M, Galatolo D, et al. Spinocerebellar ataxia 48 presenting with ataxia associated with cognitive, psychiatric, and extrapyramidal features: A report of two Italian families. Parkinsonism Relat Disord 2019; 65:91.</a></li><li><a class="nounderline abstract_t">Genis D, Ortega-Cubero S, San Nicolás H, et al. Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48). Neurology 2018; 91:e1988.</a></li><li><a class="nounderline abstract_t">Palvadeau R, Kaya-Güleç ZE, Şimşir G, et al. Cerebellar cognitive-affective syndrome preceding ataxia associated with complex extrapyramidal features in a Turkish SCA48 family. Neurogenetics 2020; 21:51.</a></li><li><a class="nounderline abstract_t">Lieto M, Riso V, Galatolo D, et al. The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families. Eur J Neurol 2020; 27:498.</a></li><li><a class="nounderline abstract_t">Whaley NR, Fujioka S, Wszolek ZK. Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics. Orphanet J Rare Dis 2011; 6:33.</a></li><li><a class="nounderline abstract_t">Silveira I, Lopes-Cendes I, Kish S, et al. Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients. Neurology 1996; 46:214.</a></li><li><a class="nounderline abstract_t">Le Ber I, Camuzat A, Castelnovo G, et al. Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. Arch Neurol 2003; 60:1097.</a></li><li><a class="nounderline abstract_t">Brusco A, Gellera C, Cagnoli C, et al. Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families. Arch Neurol 2004; 61:727.</a></li><li><a class="nounderline abstract_t">Wardle M, Majounie E, Williams NM, et al. Dentatorubral pallidoluysian atrophy in South Wales. J Neurol Neurosurg Psychiatry 2008; 79:804.</a></li><li><a class="nounderline abstract_t">Onodera O, Oyake M, Takano H, et al. Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS. Am J Hum Genet 1995; 57:1050.</a></li><li><a class="nounderline abstract_t">Egawa K, Takahashi Y, Kubota Y, et al. Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy. Epilepsia 2008; 49:2041.</a></li><li><a class="nounderline abstract_t">Koide R, Onodera O, Ikeuchi T, et al. Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings. Neurology 1997; 49:1605.</a></li><li><a class="nounderline abstract_t">Tsuji S. Dentatorubral-pallidoluysian atrophy. Handb Clin Neurol 2012; 103:587.</a></li><li><a class="nounderline abstract_t">Gövert F, Schneider SA. Huntington's disease and Huntington's disease-like syndromes: an overview. Curr Opin Neurol 2013; 26:420.</a></li><li><a class="nounderline abstract_t">Burke JR, Wingfield MS, Lewis KE, et al. The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family. Nat Genet 1994; 7:521.</a></li><li><a class="nounderline abstract_t">Nagafuchi S, Yanagisawa H, Ohsaki E, et al. Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA). Nat Genet 1994; 8:177.</a></li><li><a class="nounderline abstract_t">Yazawa I, Nukina N, Hashida H, et al. Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain. Nat Genet 1995; 10:99.</a></li><li><a class="nounderline abstract_t">Igarashi S, Koide R, Shimohata T, et al. Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch. Nat Genet 1998; 18:111.</a></li><li><a class="nounderline abstract_t">Ellerby LM, Andrusiak RL, Wellington CL, et al. Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity. J Biol Chem 1999; 274:8730.</a></li><li><a class="nounderline abstract_t">Brussino A, Gellera C, Saluto A, et al. FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia. Neurology 2005; 64:145.</a></li><li><a class="nounderline abstract_t">Leehey MA, Berry-Kravis E, Goetz CG, et al. FMR1 CGG repeat length predicts motor dysfunction in premutation carriers. Neurology 2008; 70:1397.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004; 74:1051.</a></li><li><a class="nounderline abstract_t">Rodriguez-Revenga L, Pagonabarraga J, Gómez-Anson B, et al. Motor and mental dysfunction in mother-daughter transmitted FXTAS. Neurology 2010; 75:1370.</a></li><li><a class="nounderline abstract_t">Berry-Kravis E, Potanos K, Weinberg D, et al. Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation. Ann Neurol 2005; 57:144.</a></li><li><a class="nounderline abstract_t">Oostra BA, Willemsen R. A fragile balance: FMR1 expression levels. Hum Mol Genet 2003; 12 Spec No 2:R249.</a></li><li><a class="nounderline abstract_t">Apartis E, Blancher A, Meissner WG, et al. FXTAS: new insights and the need for revised diagnostic criteria. Neurology 2012; 79:1898.</a></li><li><a class="nounderline abstract_t">Hagerman R, Hagerman P. Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome. Lancet Neurol 2013; 12:786.</a></li><li><a class="nounderline abstract_t">Hagerman PJ, Hagerman RJ. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 2004; 10:25.</a></li><li><a class="nounderline abstract_t">Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective. Am J Hum Genet 2004; 74:805.</a></li><li><a class="nounderline abstract_t">Hagerman RJ, Leehey M, Heinrichs W, et al. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 2001; 57:127.</a></li><li><a class="nounderline abstract_t">Amiri K, Hagerman RJ, Hagerman PJ. Fragile X-associated tremor/ataxia syndrome: an aging face of the fragile X gene. Arch Neurol 2008; 65:19.</a></li><li><a class="nounderline abstract_t">Jacquemont S, Hagerman RJ, Leehey M, et al. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet 2003; 72:869.</a></li><li><a class="nounderline abstract_t">Brunberg JA, Jacquemont S, Hagerman RJ, et al. Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction. AJNR Am J Neuroradiol 2002; 23:1757.</a></li><li><a class="nounderline abstract_t">Cohen S, Masyn K, Adams J, et al. Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome. Neurology 2006; 67:1426.</a></li><li><a class="nounderline abstract_t">Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006; 129:243.</a></li><li><a class="nounderline abstract_t">Salcedo-Arellano MJ, Wang JY, McLennan YA, et al. Cerebral Microbleeds in Fragile X-Associated Tremor/Ataxia Syndrome. Mov Disord 2021; 36:1935.</a></li><li><a class="nounderline abstract_t">Hall DA, Berry-Kravis E, Jacquemont S, et al. Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS). Neurology 2005; 65:299.</a></li><li><a class="nounderline abstract_t">Kamm C, Gasser T. The variable phenotype of FXTAS: a common cause of "idiopathic" disorders. Neurology 2005; 65:190.</a></li><li><a class="nounderline abstract_t">Toft M, Aasly J, Bisceglio G, et al. Parkinsonism, FXTAS, and FMR1 premutations. Mov Disord 2005; 20:230.</a></li><li><a class="nounderline abstract_t">Garcia Arocena D, Louis ED, Tassone F, et al. Screen for expanded FMR1 alleles in patients with essential tremor. Mov Disord 2004; 19:930.</a></li><li><a class="nounderline abstract_t">Kamm C, Healy DG, Quinn NP, et al. The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group. Brain 2005; 128:1855.</a></li></ol></div><div id="topicVersionRevision">Topic 6230 Version 54.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35481685" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nomenclature of Genetic Movement Disorders: Recommendations of the International Parkinson and Movement Disorder Society Task Force - An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15895552" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The wide spectrum of spinocerebellar ataxias (SCAs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030410" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Genetic background of apparently idiopathic sporadic cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7477379" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21832228" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The natural history of spinocerebellar ataxia type 1, 2, 3, and 6: a 2-year follow-up study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15477548" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Damage to the reticulotegmental nucleus of the pons in spinocerebellar ataxia type 1, 2, and 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35182509" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Whole genome sequencing for the diagnosis of neurological repeat expansion disorders in the UK: a retrospective diagnostic accuracy and prospective clinical validation study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15240431" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Brainstem neurodegeneration correlates with clinical dysfunction in SCA1 but not in SCA2. A quantitative volumetric, diffusion and proton spectroscopy MR study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9577387" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : The natural history of degenerative ataxia: a retrospective study in 466 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29553382" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Survival in patients with spinocerebellar ataxia types 1, 2, 3, and 6 (EUROSCA): a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822634" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32822634" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Conversion of individuals at risk for spinocerebellar ataxia types 1, 2, 3, and 6 to manifest ataxia (RISCA): a longitudinal cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30284037" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Spinocerebellar ataxia: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10768629" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Frequency of SCA1, SCA2, SCA3/MJD, SCA6, SCA7, and DRPLA CAG trinucleotide repeat expansion in patients with hereditary spinocerebellar ataxia from Chinese kindreds.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9106530" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The prevalence and wide clinical spectrum of the spinocerebellar ataxia type 2 trinucleotide repeat in patients with autosomal dominant cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9855520" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Incidence of dominant spinocerebellar and Friedreich triplet repeats among 361 ataxia families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11186889" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Frequency of spinocerebellar ataxia types 1, 2, 3, 6, and 7 in Australian patients with spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7668288" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Spinocerebellar ataxia type 1 and Machado-Joseph disease: incidence of CAG expansions among adult-onset ataxia patients from 311 families with dominant, recessive, or sporadic ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17417937" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Trinucleotide repeat disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8358429" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9353120" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ataxin-1 with an expanded glutamine tract alters nuclear matrix-associated structures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9778246" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Ataxin-1 nuclear localization and aggregation: role in polyglutamine-induced disease in SCA1 transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18957430" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pathogenic mechanisms of a polyglutamine-mediated neurodegenerative disease, spinocerebellar ataxia type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12965213" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The AXH module: an independently folded domain common to ataxin-1 and HBP1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21427130" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Partial loss of Tip60 slows mid-stage neurodegeneration in a spinocerebellar ataxia type 1 (SCA1) mouse model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17190598" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : ATAXIN-1 interacts with the repressor Capicua in its native complex to cause SCA1 neuropathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12741986" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Serine 776 of ataxin-1 is critical for polyglutamine-induced disease in SCA1 transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18337722" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Opposing effects of polyglutamine expansion on native protein complexes contribute to SCA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22531670" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : SCA1-phosphorylation, a regulator of Ataxin-1 function and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29526553" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : ATXN1-CIC Complex Is the Primary Driver of Cerebellar Pathology in Spinocerebellar Ataxia Type 1 through a Gain-of-Function Mechanism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21245341" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Regional rescue of spinocerebellar ataxia type 1 phenotypes by 14-3-3epsilon haploinsufficiency in mice underscores complex pathogenicity in neurodegeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23719381" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : RAS-MAPK-MSK1 pathway modulates ataxin 1 protein levels and toxicity in SCA1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30385727" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Antisense oligonucleotide-mediated ataxin-1 reduction prolongs survival in SCA1 mice and reveals disease-associated transcriptome profiles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32763910" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : miR760 regulates ATXN1 levels via interaction with its 5' untranslated region.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9339681" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : The expansion of the CAG repeat in ataxin-2 is a frequent cause of autosomal dominant spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2392220" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Autosomal dominant cerebellar ataxia: clinical analysis of 263 patients from a homogeneous population in Holguín, Cuba.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896555" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896556" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Identification of the spinocerebellar ataxia type 2 gene using a direct identification of repeat expansion and cloning technique, DIRECT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10973246" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nuclear localization or inclusion body formation of ataxin-2 are not necessary for SCA2 pathogenesis in mouse or human.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8896557" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349876" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21880993" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Massive expansion of SCA2 with autonomic dysfunction, retinitis pigmentosa, and infantile spasms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24300164" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Infantile onset spinocerebellar ataxia 2 (SCA2): a clinical report with review of previous cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10953195" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Late-onset SCA2: 33 CAG repeats are sufficient to cause disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10993999" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Spinocerebellar ataxia type 2 with parkinsonism in ethnic Chinese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9779806" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Spinocerebellar ataxia type 2 (SCA 2) in an infant with extreme CAG repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9748675" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : CAG repeat expansion in an italian family with spinocerebellar ataxia type 2 (SCA2): a clinical and genetic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8058142" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Clinical and genetic analysis of a Tunisian family with autosomal dominant cerebellar ataxia type 1 linked to the SCA2 locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8595486" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Autosomal dominant cerebellar ataxia type I in Martinique (French West Indies). Clinical and neuropathological analysis of 53 patients from three unrelated SCA2 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18413477" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Muscle excitability abnormalities in Machado-Joseph disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15534186" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Cognitive impairments in Machado-Joseph disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824264" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Autonomic dysfunction in Machado-Joseph disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23775899" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Nonmotor and extracerebellar features in Machado-Joseph disease: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18771522" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Sleep symptoms and their clinical correlates in Machado-Joseph disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7874163" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559377" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Mutations in American families with spinocerebellar ataxia (SCA) type 3: SCA3 is allelic to Machado-Joseph disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9580663" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Ataxin-3 is transported into the nucleus and associates with the nuclear matrix.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9635424" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in Drosophila.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8640226" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Expanded polyglutamine in the Machado-Joseph disease protein induces cell death in vitro and in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32978817" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : CAG Repeat Size Influences the Progression Rate of Spinocerebellar Ataxia Type 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8755926" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Autosomal dominant spinocerebellar ataxia with sensory axonal neuropathy (SCA4): clinical description and genetic localization to chromosome 16q22.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10822439" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A gene on SCA4 locus causes dominantly inherited pure cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10522902" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Clinical and MRI findings in spinocerebellar ataxia type 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22914369" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Case of infantile onset spinocerebellar ataxia type 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7874171" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Spinocerebellar ataxia type 5 in a family descended from the grandparents of President Lincoln maps to chromosome 11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16429157" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Spectrin mutations cause spinocerebellar ataxia type 5.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15122720" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Molecular epidemiology of spinocerebellar ataxia type 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9403487" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Spinocerebellar ataxia type 6: gaze-evoked and vertical nystagmus, Purkinje cell degeneration, and variable age of onset.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371901" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Clinical and molecular features of spinocerebellar ataxia type 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9371900" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Spinocerebellar ataxia type 6. Molecular and clinical features of 35 Japanese patients including one homozygous for the CAG repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8988170" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the alpha 1A-voltage-dependent calcium channel.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10964945" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The polyglutamine expansion in spinocerebellar ataxia type 6 causes a beta subunit-specific enhanced activation of P/Q-type calcium channels in Xenopus oocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10369863" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Abundant expression and cytoplasmic aggregations of [alpha]1A voltage-dependent calcium channel protein associated with neurodegeneration in spinocerebellar ataxia type 6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8898206" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9566402" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Variable clinical expression of mutations in the P/Q-type calcium channel gene in familial hemiplegic migraine. Dutch Migraine Genetics Research Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9781533" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Molecular and clinical studies in SCA-7 define a broad clinical spectrum and the infantile phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15349877" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Ataxin-7 aggregation and ubiquitination in infantile SCA7 with 180 CAG repeats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7647799" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Retinal degeneration characterizes a spinocerebellar ataxia mapping to chromosome 3p.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9288099" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9736784" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : De novo expansion of intermediate alleles in spinocerebellar ataxia 7.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10885657" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Expression analysis of ataxin-7 mRNA and protein in human brain: evidence for a widespread distribution and focal protein accumulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11030754" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Expanded polyglutamines induce neurodegeneration and trans-neuronal alterations in cerebellum and retina of SCA7 transgenic mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15099544" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Autosomal dominant cerebellar ataxias: clinical features, genetics, and pathogenesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10980728" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Spinocerebellar ataxia type 8: clinical features in a large family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10976642" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Clinical and genetic findings in Finnish ataxia patients with the spinocerebellar ataxia 8 repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060579" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Clinicopathologic investigation of a family with expanded SCA8 CTA/CTG repeats.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20373340" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : RNA-mediated neurodegeneration in repeat expansion disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192387" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : An untranslated CTG expansion causes a novel form of spinocerebellar ataxia (SCA8)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10712199" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : High germinal instability of the (CTG)n at the SCA8 locus of both expanded and normal alleles.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16804541" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Bidirectional expression of CUG and CAG expansion transcripts and intranuclear polyglutamine inclusions in spinocerebellar ataxia type 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15152344" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Spinocerebellar ataxia type 8: molecular genetic comparisons and haplotype analysis of 37 families with ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12164725" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Clinical features and ATTCT repeat expansion in spinocerebellar ataxia type 10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15505178" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Clinical phenotype of Brazilian families with spinocerebellar ataxia 10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620556" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Ethnic origin and extrapyramidal signs in an Argentinean spinocerebellar ataxia type 10 family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10072060" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Mapping of the gene for a novel spinocerebellar ataxia with pure cerebellar signs and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9973298" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Mapping of a new autosomal dominant spinocerebellar ataxia to chromosome 22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017075" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Large expansion of the ATTCT pentanucleotide repeat in spinocerebellar ataxia type 10.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10417284" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Autosomal dominant cerebellar ataxia type III: linkage in a large British family to a 7.6-cM region on chromosome 15q14-21.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18037885" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mutations in TTBK2, encoding a kinase implicated in tau phosphorylation, segregate with spinocerebellar ataxia type 11.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10581021" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27864267" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Clinical behaviour of spinocerebellar ataxia type 12 and intermediate length abnormal CAG repeats in PPP2R2B.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10820125" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Mapping of spinocerebellar ataxia 13 to chromosome 19q13.3-q13.4 in a family with autosomal dominant cerebellar ataxia and mental retardation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16501573" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Mutations in voltage-gated potassium channel KCNC3 cause degenerative and developmental central nervous system phenotypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10939565" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : A novel locus for dominant cerebellar ataxia (SCA14) maps to a 10.2-cM interval flanked by D19S206 and D19S605 on chromosome 19q13.4-qter.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14676051" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Spinocerebellar ataxia type 14 caused by a mutation in protein kinase C gamma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15618281" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Protein kinase C gamma mutations in spinocerebellar ataxia 14 increase kinase activity and alter membrane targeting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15824357" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : The clinical and genetic spectrum of spinocerebellar ataxia 14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16193476" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : New mutations in protein kinase Cgamma associated with spinocerebellar ataxia type 14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11723290" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : A new autosomal dominant pure cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445634" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : A novel autosomal dominant spinocerebellar ataxia (SCA16) linked to chromosome 8q22.1-24.1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12828938" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Spinocerebellar ataxia type 15 (sca15) maps to 3p24.2-3pter: exclusion of the ITPR1 gene, the human orthologue of an ataxic mouse mutant.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981189" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Japanese SCA families with an unusual phenotype linked to a locus overlapping with SCA15 locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17590087" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Deletion at ITPR1 underlies ataxia in mice and spinocerebellar ataxia 15 in humans.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18579805" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Total deletion and a missense mutation of ITPR1 in Japanese SCA15 families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17932120" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Heterozygous deletion of ITPR1, but not SUMF1, in spinocerebellar ataxia type 16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18310270" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : "SCA16" is really SCA15.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030759" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The contactin 4 gene locus at 3p26 is a candidate gene of SCA16.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11448935" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : SCA17, a novel autosomal dominant cerebellar ataxia caused by an expanded polyglutamine in TATA-binding protein.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36374860" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Genotype-Phenotype Correlations for ATX-TBP (SCA17): MDSGene Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17101913" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Phenotypic homogeneity of the Huntington disease-like presentation in a SCA17 family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17994014" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Polyglutamine domain modulates the TBP-TFIIB interaction: implications for its normal function and neurodegeneration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11992570" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Autosomal dominant sensory/motor neuropathy with Ataxia (SMNA): Linkage to chromosome 7q22-q32.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11284128" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Clinical and genetic analysis of a four-generation family with a distinct autosomal dominant cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384780" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Identification of a novel SCA locus ( SCA19) in a Dutch autosomal dominant cerebellar ataxia family on chromosome region 1p21-q21.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12764052" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A novel autosomal dominant spinocerebellar ataxia (SCA22) linked to chromosome 1p21-q23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280838" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Mutations in potassium channel kcnd3 cause spinocerebellar ataxia type 19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280837" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Mutations in KCND3 cause spinocerebellar ataxia type 22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23280833" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Repolarization matters: mutations in the Kv4.3 potassium channel cause SCA19/22.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14998916" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Dominantly inherited ataxia and dysphonia with dentate calcification: spinocerebellar ataxia type 20.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18801880" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : A duplication at chromosome 11q12.2-11q12.3 is associated with spinocerebellar ataxia type 20.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11160961" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Clinical features and genetic analysis of a new form of spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25070513" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : TMEM240 mutations cause spinocerebellar ataxia 21 with mental retardation and severe cognitive impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32705938" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : The Neurodevelopmental and Motor Phenotype of SCA21 (ATX-TMEM240).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306549" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Mapping of the SCA23 locus involved in autosomal dominant cerebellar ataxia to chromosome region 20p13-12.3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21035104" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Prodynorphin mutations cause the neurodegenerative disorder spinocerebellar ataxia type 23.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11960835" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : A form of inherited cerebellar ataxia with saccadic intrusions, increased saccadic speed, sensory neuropathy, and myoclonus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14681893" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Pathogenesis of clinical signs in recessive ataxia with saccadic intrusions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14705117" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Spinocerebellar ataxia with sensory neuropathy (SCA25) maps to chromosome 2p.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15732118" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Spinocerebellar ataxia type 26 maps to chromosome 19p13.3 adjacent to SCA6.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23001565" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : A conserved eEF2 coding variant in SCA26 leads to loss of translational fidelity and increased susceptibility to proteostatic insult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12489043" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : A mutation in the fibroblast growth factor 14 gene is associated with autosomal dominant cerebellar ataxia [corrected].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16211615" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Spinocerebellar ataxia associated with a mutation in the fibroblast growth factor 14 gene (SCA27): A new phenotype.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15470364" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Mutation analysis in the fibroblast growth factor 14 gene: frameshift mutation and polymorphisms in patients with inherited ataxias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36516086" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37267898" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : An intronic GAA repeat expansion in FGF14 causes the autosomal-dominant adult-onset ataxia SCA27B/ATX-FGF14.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37470282" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Natural History and Phenotypic Spectrum of GAA-FGF14 Sporadic Late-Onset Cerebellar Ataxia (SCA27B).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37224214" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Deep Intronic FGF14 GAA Repeat Expansion in Late-Onset Cerebellar Ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37399286" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Intronic FGF14 GAA repeat expansions are a common cause of ataxia syndromes with neuropathy and bilateral vestibulopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37165652" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : GAA-FGF14 ataxia (SCA27B): phenotypic profile, natural history progression and 4-aminopyridine treatment response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16251216" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : SCA28, a novel form of autosomal dominant cerebellar ataxia on chromosome 18p11.22-q11.2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20208537" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Mutations in the mitochondrial protease gene AFG3L2 cause dominant hereditary ataxia SCA28.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15623688" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Autosomal dominant congenital non-progressive ataxia overlaps with the SCA15 locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16001362" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : An autosomal dominant cerebellar ataxia linked to chromosome 16q22.1 is associated with a single-nucleotide substitution in the 5' untranslated region of the gene encoding a protein with spectrin repeat and Rho guanine-nucleotide exchange-factor domains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16116133" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A clinical, genetic, and neuropathologic study in a family with 16q-linked ADCA type III.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17030774" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Clinical features of chromosome 16q22.1 linked autosomal dominant cerebellar ataxia in Japanese.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19878914" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Spinocerebellar ataxia type 31 is associated with "inserted" penta-nucleotide repeats containing (TGGAA)n.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : SCA32: an autosomal dominant cerebellar ataxia with azoospermia maps to chromosome 7q32-q33 [abstract]</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5048218" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Erythrokeratodermia with ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24566826" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Expanding the clinical phenotype associated with ELOVL4 mutation: study of a large French-Canadian family with autosomal dominant spinocerebellar ataxia and erythrokeratodermia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26010696" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : A Novel Mutation in ELOVL4 Leading to Spinocerebellar Ataxia (SCA) With the Hot Cross Bun Sign but Lacking Erythrokeratodermia: A Broadened Spectrum of SCA34.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21106500" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : TGM6 identified as a novel causative gene of spinocerebellar ataxias using exome sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22554020" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Whole exome sequencing identifies a novel mutation in the transglutaminase 6 gene for spinocerebellar ataxia in a Chinese family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25253745" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Spinocerebellar ataxia 35: novel mutations in TGM6 with clinical and genetic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21683323" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Expansion of intronic GGCCTG hexanucleotide repeat in NOP56 causes SCA36, a type of spinocerebellar ataxia accompanied by motor neuron involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22744658" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Clinical features of SCA36: a novel spinocerebellar ataxia with motor neuron involvement (Asidan).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22753339" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : The clinical characteristics of spinocerebellar ataxia 36: a study of 2121 Japanese ataxia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22492559" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : 'Costa da Morte' ataxia is spinocerebellar ataxia 36: clinical and genetic characterization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25476002" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Spinocerebellar ataxia type 36 exists in diverse populations and can be caused by a short hexanucleotide GGCCTG repeat expansion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23700170" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : New subtype of spinocerebellar ataxia with altered vertical eye movements mapping to chromosome 1p32.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29939198" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : Clinical, genetic and neuropathological characterization of spinocerebellar ataxia type 37.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25065913" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : ELOVL5 mutations cause spinocerebellar ataxia 38.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25062847" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : A novel missense mutation in CCDC88C activates the JNK pathway and causes a dominant form of spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25477146" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Do mutations in the murine ataxia gene TRPC3 cause cerebellar ataxia in humans?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26456284" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : A Recurrent Mutation in CACNA1G Alters Cav3.1 T-Type Calcium-Channel Conduction and Causes Autosomal-Dominant Cerebellar Ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26715324" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : A mutation in the low voltage-gated calcium channel CACNA1G alters the physiological properties of the channel, causing spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27583304" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : MME mutation in dominant spinocerebellar ataxia with neuropathy (SCA43).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886343" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : Dominant Mutations in GRM1 Cause Spinocerebellar Ataxia Type 44.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29053796" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Exome sequencing and network analysis identifies shared mechanisms underlying spinocerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29474920" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : A Mild PUM1 Mutation Is Associated with Adult-Onset Ataxia, whereas Haploinsufficiency Causes Developmental Delay and Seizures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31126790" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Spinocerebellar ataxia 48 presenting with ataxia associated with cognitive, psychiatric, and extrapyramidal features: A report of two Italian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30381368" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Heterozygous STUB1 mutation causes familial ataxia with cognitive affective syndrome (SCA48).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31741143" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Cerebellar cognitive-affective syndrome preceding ataxia associated with complex extrapyramidal features in a Turkish SCA48 family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31571321" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : The complex phenotype of spinocerebellar ataxia type 48 in eight unrelated Italian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21619691" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Autosomal dominant cerebellar ataxia type I: a review of the phenotypic and genotypic characteristics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8559378" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Frequency of spinocerebellar ataxia type 1, dentatorubropallidoluysian atrophy, and Machado-Joseph disease mutations in a large group of spinocerebellar ataxia patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925365" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15148151" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Molecular genetics of hereditary spinocerebellar ataxia: mutation analysis of spinocerebellar ataxia genes and CAG/CTG repeat expansion detection in 225 Italian families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17965145" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : Dentatorubral pallidoluysian atrophy in South Wales.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7485154" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Molecular cloning of a full-length cDNA for dentatorubral-pallidoluysian atrophy and regional expressions of the expanded alleles in the CNS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18616556" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Electroclinical features of epilepsy in patients with juvenile type dentatorubral-pallidoluysian atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9409354" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Atrophy of the cerebellum and brainstem in dentatorubral pallidoluysian atrophy. Influence of CAG repeat size on MRI findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21827919" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : Dentatorubral-pallidoluysian atrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23812307" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : Huntington's disease and Huntington's disease-like syndromes: an overview.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7951323" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : The Haw River syndrome: dentatorubropallidoluysian atrophy (DRPLA) in an African-American family.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7842016" id="rid194" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>195 : Structure and expression of the gene responsible for the triplet repeat disorder, dentatorubral and pallidoluysian atrophy (DRPLA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7647802" id="rid195" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>196 : Abnormal gene product identified in hereditary dentatorubral-pallidoluysian atrophy (DRPLA) brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9462738" id="rid196" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>197 : Suppression of aggregate formation and apoptosis by transglutaminase inhibitors in cells expressing truncated DRPLA protein with an expanded polyglutamine stretch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10085113" id="rid197" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>198 : Cleavage of atrophin-1 at caspase site aspartic acid 109 modulates cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15642922" id="rid198" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>199 : FMR1 gene premutation is a frequent genetic cause of late-onset sporadic cerebellar ataxia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18057320" id="rid199" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>200 : FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15065016" id="rid200" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>201 : Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20938029" id="rid201" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>202 : Motor and mental dysfunction in mother-daughter transmitted FXTAS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15622531" id="rid202" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>203 : Fragile X-associated tremor/ataxia syndrome in sisters related to X-inactivation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952862" id="rid203" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>204 : A fragile balance: FMR1 expression levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23077007" id="rid204" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>205 : FXTAS: new insights and the need for revised diagnostic criteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23867198" id="rid205" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>206 : Advances in clinical and molecular understanding of the FMR1 premutation and fragile X-associated tremor/ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14994285" id="rid206" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>207 : Fragile X-associated tremor/ataxia syndrome (FXTAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15052536" id="rid207" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>208 : The fragile-X premutation: a maturing perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11445641" id="rid208" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>209 : Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18195136" id="rid209" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>210 : Fragile X-associated tremor/ataxia syndrome: an aging face of the fragile X gene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12638084" id="rid210" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>211 : Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12427636" id="rid211" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>212 : Fragile X premutation carriers: characteristic MR imaging findings of adult male patients with progressive cerebellar and cognitive dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17060569" id="rid212" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>213 : Molecular and imaging correlates of the fragile X-associated tremor/ataxia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16332642" id="rid213" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>214 : Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33760253" id="rid214" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>215 : Cerebral Microbleeds in Fragile X-Associated Tremor/Ataxia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043804" id="rid215" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>216 : Initial diagnoses given to persons with the fragile X associated tremor/ataxia syndrome (FXTAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16043784" id="rid216" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>217 : The variable phenotype of FXTAS: a common cause of "idiopathic" disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15390127" id="rid217" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>218 : Parkinsonism, FXTAS, and FMR1 premutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15300658" id="rid218" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>219 : Screen for expanded FMR1 alleles in patients with essential tremor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15947063" id="rid219" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>220 : The fragile X tremor ataxia syndrome in the differential diagnosis of multiple system atrophy: data from the EMSA Study Group.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
